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Abstract	
Non-alcoholic	fatty	liver	disease	(NAFLD)	and	Type	2	diabetes	mellitus	(T2DM)	are	hallmarks	
of	the	metabolic	syndrome	(MS),	a	major	challenge,	particularly	in	Western	societies.	Neutral	
lipid	accumulation	 in	 lipid	droplets	 (LDs)	of	hepatocytes	contributes	 to	the	development	of	
fatty	liver	and	NAFLD.	Together	with	insulin	resistance	and	inflammation,	this	often	leads	to	
liver	failure	or	development	of	hepatocarcinoma.	Current	pharmacological	treatments	have	
limitations	and	 identification	of	new	 targets	 that	 reduce	neutral	 lipid	 storage	 is	 an	area	of	
intense	research.	Hence,	identification	of	players	that	contribute	to	triglyceride	accumulation	
and	 LD	 formation	 could	deliver	new	 targets	 for	NAFLD	prevention.	Over	 the	years,	Grewal	
and	colleagues	have	intensively	studied	Annexin	A6	(AnxA6),	a	calcium	(Ca2+)	and	membrane	
binding	protein	in	the	context	of	growth	factor	receptor	signalling,	cholesterol	transport,	as	
well	 as	 liver	 function	and	 triglyceride	metabolism.	Recently,	using	 fluorescence	microscopy	
and	 flow	 cytometry	 approaches,	 the	 Grewal	 laboratory	 identified	 that	 upregulation	 of	
hepatic	AnxA6	increased	LD	numbers	and	triglyceride	accumulation	upon	loading	with	oleic	
acid	(OA),	possibly	involving	cytoplasmic	phospholipase	A2	(cPLA2)	-dependent	pathways.	Co-
localization	with	LD	markers	suggested	that	AnxA6	may	be	associated	with	LD.	This	project	
aimed	to	substantiate	these	findings.	Indeed,	triglyceride	levels	in	isolated	LD	fractions	from	
AnxA6	overexpressing	HuH7	hepatocytes	were	elevated	compared	to	controls.	Western	blot	
analysis	after	subcellular	 fractionation	of	rat	 liver	tissue	 identified	the	association	of	AnxA6	
with	LD-enriched	fractions.	OA,	as	well	as	other	lipid-modifying	conditions,	increased	AnxA6	
protein	 expression	 in	 HuH7	 hepatocytes,	 while	 mRNA	 levels	 remained	 unchanged	 in	 OA-
incubated	 hepatic	 cell	 lines.	 cPLA2	 phosphorylation	 patterns,	which	 are	 indicative	 of	 cPLA2	
activity,	 are	 altered	 in	HuH7	 cell	 lines	with	 stable	overexpression	or	 knockdown	of	AnxA6.	
Analysis	 of	 AnxA6	 expression	 in	 genetic	 and	 dietary	 mouse	 models	 of	 insulin	 resistance,	
diabetes	and	obesity	reveal	only	minor	changes	 in	AnxA6	levels,	suggesting	that	changes	 in	
cellular	localization	and	function	rather	than	expression	could	trigger	an	involvement	in	the	
development	of	fatty	liver.	In	summary,	this	study	supports	recent	findings	from	the	Grewal	
laboratory	 that	 AnxA6	 is	 a	 novel	 regulator	 in	 LD	 formation	 in	 hepatocytes.	 Hence,	 tissue-
specific	inhibition	of	AnxA6-dependent	pathways	that	promote	LD	formation	in	hepatocytes	
could	 contribute	 to	 develop	 novel	 therapeutic	 strategies	 for	 the	 prevention	 of	 fatty	 liver	
disease.		
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1 
1.	Introduction	
1.1	Non-alcoholic	fatty	liver	disease	(NAFLD)	and	metabolic	syndrome	(MS)	
Non-alcoholic	 fatty	 liver	 disease	 (NAFLD)	 is	 the	 hepatic	manifestation	 of	 the	metabolic	
syndrome	(MS)	and	represents	a	major	challenge	particularly	to	the	Western	World	(1,	2).	
Indeed	 in	the	United	States	NAFLD	has	become	the	most	common	form	of	chronic	 liver	
disease	and	this	trend	has	been	recognized	worldwide	(3,	4).	 It	 is	estimated	that	NAFLD	
affects	up	to	30%	of	adults	in	the	US	and	other	Western	countries	(2,	5).		
	
NAFLD	 is	 an	 umbrella	 term,	 which	 encompasses	 an	 array	 of	 clinicopathologic	 entities	
histologically	 characterized	 by	 macro-vesicular	 hepatic	 steatosis	 in	 the	 absence	 of	
significant	alcohol	use	or	amounts	considered	to	be	harmful	to	the	liver	(less	than	20g	per	
day,	approximately	2	standard	drinks)	(2-4,	6,	7).		
	
The	 spectrum	 of	 conditions	 ranges	 from	 simple	 hepatic	 steatosis	 and	 hepatic	 steatosis	
with	nonspecific	 inflammation,	which	are	believed	to	be	generally	benign	in	nature	 (Fig.	
1).	To	the	more	severe	non-alcoholic	steatohepatitis	(NASH),	which	may	progress	to	liver	
cirrhosis,	 liver	 failure	 and	 even	 hepatocellular	 carcinoma	 (HCC)	 (3,	 6,	 8).	NASH	 is	 often	
accompanied	by	hepatocellular	damage	plus	inflammation	and/or	fibrosis	(9,	10).		
	
	
	
	
	
	
	
	
	
	
Figure	 1:	NAFLD:	 (A)	 Indicates	 the	 disease	 spectrum	of	NAFLD.	 (B)	Histological	 sections	
illustrating	 the	 differing	 stages	 of	 disease.	 Portal	 Vein	 (PT)	 and	 Central	 Vein	 (CV)	 are	
shown	(11).	
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Epidemiological	 studies	 suggest	 that	 NAFLD	may	 affect	 any	 age	 and	 ethnic	 group,	 and	
though	 typically	 a	 disease	 affecting	 Western	 Societies,	 it	 has	 also	 reached	 epidemic	
proportions	 in	 ‘low	 risk’	 communities	 (9,	 12,	 13).	 There	 is	 a	 reported	 29%	 NAFLD	
prevalence	among	healthy	Japanese	adults,	 indicating	that	NAFLD	has	reached	epidemic	
proportions	even	in	different	populations	around	the	world	(14).	The	overall	prevalence	
of	NAFLD	in	children	is	2.6%,	but	increases	up	to	53%	in	obese	children	(9).	
	
The	worldwide	 increases	 in	 the	 prevalence	 of	 NAFLD	 have	 been	 shown	 to	 parallel	 the	
increases	in	the	prevalence	of	its	associated	risk	factors,	which	include	obesity,	diabetes	
mellitus	and	hyperlipidemia	(14-16).	All	are	components	of	the	metabolic	syndrome	(MS)	
and	 lead	 to	 cardio-metabolic	 complications	 (3,	 17).	 It	 has	 been	 stipulated	 that	 the	
prevalence	 of	MS	 in	 NAFLD	 could	 vary	 from	 18%	 in	 normal-weight	 patients	 to	 67%	 in	
obese	patients	(5).	Indeed	over	90%	of	patients	with	NAFLD	are	said	to	have	at	least	one	
feature	of	MS	(14).	Therein	lies	a	complex	yet	close	relationship	between	obesity,	insulin	
and	NAFLD	(10).	
	
1.2	The	association	of	NAFLD	with	diabetes	and	insulin	resistance	
In	a	long	term	follow-up	study	by	Mattias	et	al,	most	patients	with	NAFLD	were	shown	to	
have	developed	diabetes	or	 impaired	glucose	tolerance	(17).	Further,	more	pronounced	
insulin	 resistance	 and	weight	 gain	was	 shown	 to	be	 associated	with	 the	progression	of	
liver	fibrosis	(17).	A	review	by	Gaggini	et	al,	demonstrated	that	NAFLD	is	most	prevalent	
among	obese	patients	(57%)	and	patients	suffering	with	type	2	diabetes	mellitus	(T2DM)	
(70%),	 independent	 of	 their	 degree	 of	 obesity	 (5).	 The	 prevalence	 jumped	 to	 90%	 in	
morbidly	obese	people	(5).	Insulin	sensitivity	is	shown	in	patients	with	NAFLD	at	the	level	
of	the	muscle,	liver	and	adipose	tissue	(5,	18).	Several	epidemiological	reports	suggest	up	
to	85%	of	NAFLD	suffers	are	 insulin	resistant	and	have	 impaired	glucose	metabolism,	 in	
the	form	of	prediabetes	or	T2DM,	of	which	they	are	unaware	(5).	Further,	quite	possibly	
due	 to	 the	 complications	 of	 insulin	 resistance	 such	 as	 vascular	 disease	 and	 NAFLD	
cirrhosis,	 patients	diagnosed	with	NAFLD	appear	 to	have	an	 increased	mortality	 rate	 in	
comparison	to	the	general	population	 (9).	A	significant	study	by	Ong	et	al	 found	overall	
mortality	and	liver-related	mortality	was	9-fold	higher	among	persons	with	NAFLD	(19).			
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Metabolic	 abnormalities	 identified	 in	 patients	 with	 NAFLD	 have	 also	 been	 shown	 to	
promote	 atherosclerosis	 (5).	 Studies	 have	 indicated	 increased	 carotid	 intima	 media	
thickness	(IMT)	and	coronary	atherosclerosis	 in	NAFLD	patients	(5).	Even	in	the	absence	
of	MS,	as	profoundly	shown	by	the	RISC	study,	NAFLD	patients	are	more	prone	to	early	
carotid	atherosclerosis	(20).	Further,	it	is	also	shown	that	coronary	artery	disease	(CAD)	is	
a	major	cause	of	death	in	NAFLD	patients	(5,	21).	Due	to	the	fact	that	the	hepatic	fat	 is	
often	associated	with	the	cardiac	fat,	and	in	conjunction	with	increased	insulin	resistance	
affects	not	only	the	liver	but	also	numerous	other	tissues	such	as	the	heart	(5,	21).		
	
In	 particular	 insulin	 resistance	 is	 believed	 to	 have	 a	 central	 role	 in	 the	pathogenesis	 of	
NAFLD	(3).	 Insulin	resistance	leads	to	a	resistance	in	the	anti-lipolytic	effect	of	 insulin	 in	
the	 adipose	 tissue	 accompanied	 with	 an	 increase	 of	 free	 fatty	 acids	 (FFAs)	 (5).	 The	
increase	 in	FFAs	 induces	mitochondrial	dysfunction	and	 the	development	of	 lipotoxicity	
(5,	 18).	 Figure	 2	 illustrates	 that	 insulin	 resistance	 is	 associated	 with	 increased	 fat	
accumulation	 in	 the	 liver,	 which	 in	 turn,	 is	 associated	 with	 oxidative	 stress	 and	 lipid	
peroxidation	 (2).	 Increase	 of	 FFAs	 flux	 leads	 to	 increased	 hepatic	 triglyceride	 (TG)	
accumulation,	 a	 consequence	 of	 the	 saturation	 of	 the	 up-regulated	 assembly	 and	
secretion	of	very	low-density	lipoproteins	(VLDL)	and	of	fatty	acid	oxidation	pathways	in	
hepatocytes	(5,	22).		
	
	
	
	
	
	
	
	
Figure	2:	Link	between	insulin	resistance	and	NAFLD	(5).	ApoB,	apolipoprotein	B;	DNL,	de	
novo	 lipogenesis;	 FFA,	 free	 fatty	 acids;	 HDL,	 high	 density	 lipoprotein;	 LDL,	 low	 density	
lipoprotein;	PAI-1;	plasminogen	activator	inhibitor-1;	T2DM,	type	2	diabetes	mellitus;	TG,	
triglycerides;	VLDL,	very	low	density	lipoprotein.	
Nutrients 2013, 5 1550 
 
 
indirectly following liberation of lipolytic products (such as FFA and lysolecithin) which may activate 
pro-inflammatory signalling pathways in endothelial cells [51]. 
Figure 4. Link between insulin resistance and metabolic dyslipidemia. Insulin resistance is 
associated with an increase of free fatty acids (FFAs) flux that contributes to increased TG 
production that, in turn, stimulate assembly and secretion of VLDL in hepatocytes. Fat 
accumulation in the liver is associated with oxidative stress and lipid peroxidation. 
Furthermore NAFLD subjects have increased secretion of inflammatory markers, plasma 
glucose and a decrease in HDL concentration. The consequence of this physiological 
dysfunction is increased risk for the development of diabetes and atherosclerosis and 
increased risk for coronary artery disease. 
 
In patients with NAFLD adiponectin concentrations are decreased compared to normal subjects [52,53], 
despite higher lipolysis and fatty acid concentrations associated with increased hepatic and systemic 
fatty acid oxidation. It is well established that adiponectin activates AMPK and peroxisome 
proliferator-activated receptor (PPAR)-α,  thus  stimulating  fatty  acid  oxidation  in  liver  and  muscle  [54]. 
Adiponectin levels also correlate inversely with plasma TGs, positively with HDL-cholesterol levels 
and LDL size, suggesting a role in lipoprotein metabolism [26,55]. Thus, low adiponectin levels in 
NAFLD can be seen as a limit in the capacity of further increase lipid oxidation in response to FFA 
overload, redirecting FFA towards re-esterification. 
Fatty Liver and Metabolic Syndrome 
It is not surprising that many studies have highlighted the association between NAFLD and several 
factors of metabolic syndrome, especially abdominal obesity, insulin resistance, increased serum 
triglycerides and small dense LDL and low HDL [7,25,26,44,56–60] (Figure 4). It has also been 
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Further	physiological	dysfunction,	as	a	consequence	of	saturation	of	fatty	acid	oxidation	is	
provided	 by	 an	 increased	 secretion	 of	 inflammatory	 markers,	 plasma	 glucose	 and	
decreased	 high	 density	 lipoprotein	 (HDL)	 concentration	 (5),	 increasing	 the	 risk	 of	 the	
development	of	diabetes,	atherosclerosis	and	CAD	(5,	22).											
	
1.3	Hepatic	FA	and	TG	metabolism	in	NAFLD	
Consequently,	 numerous	 reviews	have	 implicated	 the	net	 retention	of	 lipids,	 namely	 in	
the	 form	of	TGs	as	a	prerequisite	 in	 the	pathogenesis	of	NAFLD	 (10,	22,	23).	Metabolic	
abnormalities	 and	 conditions	 of	 stress	 (such	 as	 obesity,	 imbalanced	 nutrition	 and	 drug	
induced	 liver	 injury)	 affect	 pathways	 of	 uptake,	 synthesis,	 degradation,	 or	 secretion	 in	
hepatic	lipid	metabolism,	as	outlined	in	Figure	3	(11,	24).				
	
																														 	
Figure	3:	Pathways	involved	in	hepatic	lipid	metabolism	(11).	
	
The	 three	 main	 sources	 that	 help	 derive	 the	 fatty	 acids	 (FAs)	 used	 for	 hepatic	 TG	
formation	 as	 shown	 in	 Figures	 3-4:	 Free	 fatty	 acids	 (FFAs)	 have	 three	main	 fates	 (11),	
namely	diet,	de	novo	 synthesis	and	adipose	 tissue	 (11,	24).	They	can	be	metabolized	 in	
the	mitochondira	by	b	 oxidation	 (b-OX)	 to	produce	energy	 and	 ketone	bodies	 (11,	 25).	
They	may	 be	 esterified	 to	 TG	 and	 stored	 in	 lipid	 droplets,	 or	 they	may	 be	 coupled	 to	
apolipoproteins,	 in	particular	apoB,	and	packaged	as	 constituents	of	VLDL	and	 secreted	
into	the	blood	(11,	22).				
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Figure	 4:	 The	 three	 main	 fates	 of	 FFAs	 (11).	 ApoB,	 apolipoprotein	 B;	 ATGL,	 adipose	
triglyceride	 lipase;	b-Ox,	b-oxidation;	 ChREBP,	 carbohydrate-responsive	 element-binding	
protein;	 Chylo,	 chylomicron;	 FFA,	 free	 fatty	 acid;	 SREBP-1c,	 sterol	 regulatory	 element-
binding	protein	1;	TCA,	tricarboxylic	acid	(TCA)	cycle;	VLDL,	very	low	density	lipoprotein.	
	
As	highlighted	in	the	review	by	Medina	et	al,	the	liver	may	defend	itself	from	FFA-induced	
toxicity	through	esterification	and	TG	formation,	oxidation,	or	the	synthesis	and	release	of	
VLDLs	 (26).	 Further,	 under	 normal	 conditions	 in	 the	 liver	 insulin	 inhibits	 glucose	
production	 and	 promotes	 fatty	 acid	 synthesis	 (11).	 However,	 under	 hyperlinsulinemic	
conditions,	 there	 is	 a	 diminishment	 of	 the	 inhibitory	 effect	 of	 insulin	 on	 glucose	
production,	yet	the	stimulatory	effect	of	insulin	on	lipogensis	is	retained	(11,	20).	Hence	
as	 stipulated	 in	 a	 review	 by	Greenberg	et	 al,	 insulin	 resistance	 is	marked	 by	 increased	
hepatic	 gluconeogensis	 and	 reduced	 glycogen	 formation	 (27).	 Consequently,	 the	
imbalance	between	TG	acquisition	 (from	circulating	 lipid	uptake	or	de	novo	 lipogenesis)	
and	 removal	 (lipid	 disposal	 via	 FFA	 oxidation	 or	 TG-rich	 lipoprotein	 secretion)	 is	 what	
gives	rise	to	hepatic	steatosis	(11,	22).		
	
Due	 to	 the	 benign	 nature	 of	 hepatic	 steotsis,	 it	 is	 unlikely	 that	 the	 hepatic	 lipid	
accumulation	alone	would	result	in	universal	hepatic	injury	(7).	Studies	suggest	the	need	
of	additional	secondary	 insults	on	the	steatotic	 liver	resulting	 in	the	progression	of	 liver	
disease,	characterized	by	inflammation	and	hepatocellular	degeneration	(28).	Medina	and	
associates	demonstrated	 that	 ‘exaggerated’	 levels	of	 FFA,	 through	3	main	mechanisms,	
synthesize glycogen but instead is quantitative-
ly converted to glyceraldehyde-3-phosphate, pro-
viding substrate for de novo lipogenesis. The
average yearly consumption of fructose has pro-
gressively increased and likely contributes to the
increasing prevalence of NAFLD.
What Is the Relationship Between Obesity,
Insulin Resistance, and Hepatic Steatosis?
The finding that genetic diseases that promote
flux of energy substrates to fatty acids, such as
glycogen storage disease type 1a and citrin defi-
ciency, cause s eatosis even in the absence of in-
sulin resistance indicates that increased flux of FFA
to the liver is sufficient to cause steatosis (13, 14).
In obese individuals, the increased supply of
FFA to the liver from the diet, from adipose tis-
sue, and through increased de novo lipogenesis
all serve to promote hepatic steatosis. The relative
contributions of the three pathways to hepatic
steatosis in humans have been defined in only one
study: Donnelly et al. (18) reported that 59% of
hepatic fat is derived from circulating FFAs, with
lesser contributions from de novo lipogenesis
(26%) and diet (15%).
Amaj r unresolvedquestion iswhetherNAFLD
is a cause or consequence of insulin resistance. In
liver, insulin inhibits glucose production and pro-
motes fatty acid synthesis. With the development
of hepatic insulin resistance, the inhibitory effect
of insulin on glucose production is diminished,
whereas the stimulatory effect of insulin on lipogen-
esis is retained (19). Insulin resistance is strongly
correlated with steatosis, and interventions that
ameliorate insulin resistance lead to lower insulin
levels and decreased liver fat content. Multiple
animal models support a direct causal relation-
ship between insulin resistance, hyperinsulinemia,
and hepatic steatosis (4). Evidence that insulin
resistance causes steatosis in humans derives from
patients with mutations in AKT2 (20). These pa-
tients have profound resistance to the glucoreg-
ulatory actions of insulin but presumably retain
sensitivity to the lipogenic effects of the hormone.
Studies of metastatic insulin-secreting tumors
(insulinomas) and from pancreatic islet cell trans-
plants provide further evidence that insulin di-
rectly promotes fat accumulation in liver cells.
Hepatocytes surrounding metastatic insulinomas
become engorged with TGs, as do hepatocytes
surrounding transplanted islet cells (21).
The coincident occurrence of hepatic steatosis
and insulin resistance has led to the hypothesis
that excess TG in liver causes insulin resistance.
Hepatic steatosis and insulin resistance occur to-
gether in several strains of genetically modified
mice (4, 22). However, the notion that hepatic
steat sis causes insulin resistance is contradicted
by observations in mice with defects in diverse
pathways that cause hepatic steatosis without in-
sulin resistance. Mice with reduced fatty acid syn-
thesis (23), mobilization (24), or oxidation (4), as
well as defective cytokine signaling (25) or cho-
line synthesis (26), maintain normal or improved
insulin sensitivity despite hepatic TG
accumulation. TG may be a marker
for another molecule that interferes
with insulin action, such as diacyl-
glycerol (DAG), long-chain acyl-CoA,
or ceramide. However, hepatic accu-
mulation of any of these lipids does
not invariably produce insulin resist-
ance, at least in mice [for review, see
(22)]. It remains possible that these
lipids contribute to insulin resistance
only if they accumulate within spe-
cific subcellular compartments or if
they have a particular complement of
fatty acids.
In humans, naturally occurringmu-
tations provide a powerful tool to
untangle mechanistic relationships
between highly correlated metabolic
traits. If increased hepatic TG content
causes insulin resistance, then indi-
viduals with genetic variants that pro-
mote hepatic steatosis should be at
increased risk of developing insulin
resistance. An increasing number of
Mendelian genetic defects have un-
coupled these two variables. Individ-
uals with inactivating mutations in
APOB have increased levels of he-
patic TG yet maintain normal insulin
sensitivity (15). Patients with auto-
somal recessive disorders caused by
mutations in either ATGL or CGI58
have severe steatosis but are not insulin resistant
[reviewed in (12)]. In population-based studies, a
genetic variant in PNPLA3 that is associated with
hepatic steatosis is not associated with insulin re-
sistance (see below) (5). Sequence variants in
APOC3 have been associated with both hepatic
steatosis and insulin resistance (25), but this as-
sociation was not observed in other independent
populations (26, 27). Thus, the preponderance of
evidence is not compatible with the hypothesis
that TG accumulation in hepatocytes causes in-
sulin resistance in humans.
Genetic Risk Factors for Hepatic Steatosis
Although obesity and insulin resistance are the
most prevalent risk factors for NAFLD, hepatic
fat content varies substantially among individuals
with equivalent adiposity, indicating that other
factors contribute to this condition. One of these
factors is gender. Before age 60, men are signif-
icantly more likely to develop steatosis than are
women (16), but at older ages the disorder is
more prevalent in women. Reasons for this gen-
der dimorphism are not known. Another factor
is ethnicity. In the Dallas Heart Study, hepatic
stea osis was found in 45% of Hispanics, 33% of
individuals of European ancestry, and 24% of
African Americans (16). The higher prevalence
of hepatic steatosis in Hispanics is due in part to
a higher prevalence of obesity and insulin resist-
ance in this population, but the lower prevalence
in African Americans cannot be explained by
Glucose
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Fig. 2. Metabolism of TG in the liver. The three major sources of FFAs are diet, endogenous synthesis, and peripheral
tissues. FFAs have four possible fates. They can be metabolized by b oxidation (b-OX) in mitochondria, esterified and
stored as TG in lipid droplets, used to form other lipids (not shown), or pack ged w th a oB into VLDL and secreted into
blood. Processes that increase FFA and TG input or reduce FFA and TG output cause hepatic steatosis. Carbohydrate
intake increases glucose and insulin levels, which activate two transcription factors in the liver that promote de novo
lipog nesis: ChREBP and SREBP-1c. Insulin inhibits lipolysis in adipose tissue by sup ressing ATGL. Chylo, chylo-
micron; TCA, tricarboxylic acid.
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leads	to	deleterious	secondary	effects	for	the	liver,	resulting	in	cellular	injury	(26).	These	
mechanisms	include	(i)	the	de	novo	synthesis	of	ceramides	which	cause	hepatic	apoptosis,	
a	 frequent	 mechanism	 of	 cell	 death;	 (ii)	 the	 interference	 with	 intracellular	
phosphorylation	 processes	 which	 may	 result	 in	 resistance	 to	 insulin;	 (iii)	 and	 lipid	
peroxidation	 and	 cytokine	 induction,	 a	 consequence	 of	 oxygen	 radicals	 generated	
through	FFA	oxidation	(26,	27).	Recently,	it	has	also	been	shown	that	swollen	lipid-laden	
hepatocytes	and	fibrosis	may	result	in	an	inflammatory	response	(22).	The	consequence	is	
an	 architectural	 distortion	 impairing	 hepatocyte	 oxygen	 and	 nutrient	 exchange	 (26).	
Overall,	it	is	agreed	that	oxidative	stress	and	cytokines	triggered	by	excessive	hepatic	lipid	
accumulation	 are	 the	main	 effectors	 of	 this	 second	 hit	 causing	 the	 vulnerable	 liver	 to	
undergo	further	injury	(26).		
	
1.4	The	lipid	droplet	(LD)	
Neutral	 lipids	 in	hepatocytes,	 including	 triacylglycerol	 (TAG)	and	 cholesteryl	 esters	 (CE),	
are	stored	in	lipid	droplets	(LD).	Hence,	in	recent	years	disease	states	such	as	NAFLD	have	
redefined	 the	 LD	 as	 no	 longer	 an	 inert	 storage	 of	 lipid	 esters	 but	 as	 an	 authentic	 and	
highly	dynamic	organelle	actively	engaged	in	multiple	functions,	namely	lipid	homeostasis	
(10,	29).	In	fact,	LDs	are	not	unique	to	hepatic	tissue,	but	represent	organelles	found	in	all	
eukaryotic	 cells,	 specialized	 in	 storing	and	 supplying	 lipids.	 The	 LD	 consists	of	 a	 core	of	
neutral	lipids,	triacylglycerol	and	cholesteryl	esters,	surrounded	by	a	unique	monolayer	of	
phospholipids	and	cholesterol	that	interacts	with	a	variety	of	proteins	(30,	31).	Hence,	LDs	
are	central	to	lipid	homeostasis,	providing	substrates	for	energy	metabolism,	membrane	
synthesis,	and	production	of	lipoproteins,	bile	salts,	or	hormones.	As	excess	lipid	storage	
has	been	linked	to	obesity,	diabetes,	and	atherosclerosis	[3,	4],	the	regulatory	circuits	that	
control	the	quantity	and	dimensions	of	LD	has	received	increased	attention.		
	
Though	the	exact	mechanism	of	the	formation	of	lipid	droplet	formation	in	hepatocytes	is	
not	fully	known,	an	extensive	review	by	Sahini	et	al	summarised	three	possible	models	as	
shown	in	Figure	5	(10,	12,	13).	
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Figure	 5:	 Mechanisms	 involved	 in	 the	 formation	 of	 LD	 in	 hepatocytes	 (10).	 	 ER,	
endoplasmic	reticulum;	LD,	lipid	droplet.	
	
The	bicellular	model	proposes	that	 the	LD	 is	 initially	 located	between	the	bilayer	of	 the	
endoplasmic	reticulum	(ER)	in	the	shape	of	a	lens	and	must	undergo	excision,	through	the	
rearrangement	of	 the	membrane	structure	so	as	 to	 form	a	stable	 lipid	droplet	 (10,	32).	
Intermediate	molecules	aid	 the	membrane	rearrangement	and	hence	 the	model	aids	 in	
the	 understanding	 of	 how	 particles	move	 into	 the	 cytosol	 via	 the	 LD	 (10,	 12,	 13).	 The	
vesicular	 budding	 model	 encompasses	 general	 vesicle	 budding	 through	 a	 secretary	
pathway.	 The	 pathway	 is	 followed	 into	 the	 ER	 specific	 domain,	 and	 being	 rich	 in	 lipid	
synthesis,	 the	 vesicle	 remains	 attached	 to	 ER	 membrane	 (10,	 32).	 However,	 the	 most	
widely	accepted	model	 for	 lipid	droplet	 formation	 is	 the	ER	domain	and	budding	model	
(10).	As	illustrated	in	Figure	5	there	is	lipid	accumulation	in	the	form	of	glycerol	and	esters	
within	 the	 phospholipid	 bilayer	 of	 the	 ER.	 As	 the	 neutral	 lipids	 increase,	 they	 form	 a	
blister	or	‘lens-like’	structure	which	eventuates	into	a	lipid	droplet	and	buds	out	of	the	ER	
membrane	(10).	
	
organic pool while proteins floating in it are needed for the mobil-
ity, signalling and cellular function of lipid bodies [147–149]. A
relationship exists between the morphology of lipid droplets, lipo-
genesis in non-adipoyctes and protection from lipolysis [150–154].
The exact mechanism by which lipid droplets are formed in
hepatocytes is not fully understood. Three concepts have been pro-
posed to understand the mechanism of LD formation (Fig. 3). The
Bicellar model suggests that LDs are initially formed as a lens lo-
cated between the bilayer of ER to undergo excision where further
intermediate molecules help in the rearrangement of the structure
to form a stable droplet. This model aids in understanding of how
the particles use the ER lumen and move into cytosol by harbour-
ing the lipid bodies [155,156]. In the vesicular budding model the
general vesicle budding occurs through a secretory pathway and is
followed in the ER specific domain region rich in lipid synthesis. In
turn the vesicle remains in contact with the ER membrane [157].
The most widely accepted theory of LD biogenesis is the ER domain
and the budding model. The model implies that the neutral glyc-
erol and esters accumulate within the phospholipid bilayer of the
ER and the bilayer gradually separates with the increasing neutral
lipids that form a blister or a lens like structure and grows into a
lipid droplet [156]. Once the nascent droplet is formed, it buds
out of the ER membrane (Fig. 3).
3.2. Proteins associated with lipid droplet formation and maintenance
3.2.1. Perilipins
Exclusively, perilipins are a group of proteins on the surface of
the LDs with variable expression based on the phase of LD growth
and the type of association during cellular process [45]. All perili-
pins associate with hepatic LDs during fatty liver disease, and per-
ilipin A also known as Perilipin1 plays a prominent role in the
regulation of lipolysis [158]. Perilipin4 (S3–12) is associated with
the nascent droplets and its genetic variations is closely associated
with human obesity related abnormalities [159]. Both proteins are
present in adipocytes. Perilipin2 (ADRP – adipose differentiation
related protein) is ubiquitouly expressed and interacts with cyto-
plasmic LDs to protect the droplets from the action of lipases
(HSL-hormone sensitive lipase, ATGL – adipose triglyceride lipase
found in adipocytes) [145]. Perilipin3 (TIP47 – Tail interacting pro-
tein) localises on the surface of the LDs during the diacylglycerol
production and may be important during the nascent LD expansion
[45,146]. Through its C-terminal domain Perilipin5 (LSDP5 – lipid
storage droplet protein 5) facilitates close proximity between
mitochondria and the lipid droplets to influence LD hydrolysis
[159–161]. Perilipins maintain the TG content in LD of hepatocytes
and are essential in the overall lipid turnover of LD and therefore in
the pathology of NAFLD. Perilipin1 was identified on lipid droplets
of hepatocytes during fatty liver condition [8]. Perilipin5 protects
the LDs from lipid mobilisation in hepatocytes. The presence of
perilipin2 on the LD is greatly influenced by the lipid content in
the cell. Reduced fatty acid (FA) synthesis results in degradation
of this protein via proteasomal degradation. In hepatocytes perili-
pin2 plays an important role in lipid storage and the biogenesis of
LD but also participates in the control of VLDL secretion [162].
During liver injury, the expression of perilipin2 is significantly in-
creased and found to reside prominently on the LD surface of hepa-
tocytes [163]. Obese mice treated with perilipin2 anti-sense
oligonucleotide (ASO) showed improvement in insulin sensitivity
and reduced steatosis by affecting the lipid burden and lipid
biogenesis in hepatocytes [164]. Likewise, perilipin3 is one of the
major proteins involved in the regulation of LD biogenesis and pre-
serves TG content in hepatocytes similar to that of perilipin2. Both
perilipins appear on smaller lipid droplets whereas perilipin5 coat
the larger droplets. Of note, obese mice on a high fat diet increased
liver expression of perilipin3. When treated with perilipin3-ASO
these mice improved as was seen in mice treated with perili-
pin2-ASO to suggest these perilipins to have similar roles in LD
synthesis and maintenance of lipid content [165]. The interchang-
ing of perilipins at different stages of LD growth represents their
Fig. 3. Models of LD formation through stress within the endoplasmic reticulum (the figure has been adapted from [156]).
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Besides	 establishing	models	 to	 explain	 the	origin	 and	 formation	of	 LD,	much	effort	 has	
been	put	into	the	identification	of	molecular	players	that	determine	LD	number	and	size.	
Ranging	from	a	large,	single	LD	in	adipocytes	to	more	than	hundred	small	LDs	(<1	μm)	in	
other	 cell	 types,	 including	 hepatocytes,	 they	 are	 complex	 and	 involve	 a	 substantial	
collection	of	structural,	signaling	proteins	and	lipid-modifying	enzymes	associated	with	LD	
(33-36).	 This	 includes	 the	 well-characterized	 PAT	 (perilipin-adipophilin-TIP47)	 family	 of	
proteins	(35,	36),	but	also	enzymes	involved	in	TAG	and	CE	synthesis	and	FA/cholesterol	
mobilization,	 such	 as	 acyl-CoA	 synthetases,	 diacylglycerol	 acyltransferase,	 acetyl-
coenzyme	 A	 acetyltransferase	 (37),	 and	 several	 hydrolases	 (hormone	 sensitive	 lipase,	
adipose	 triglyceride	 lipase).	 As	 outlined	 above,	 neutral	 lipid	 accumulation	 in	 the	 ER	
probably	drives	de	novo	LD	formation	(31)	and	although	the	other	models	listed	exist	(38),	
inhibition	of	enzymes	involved	in	triglyceride	synthetic	pathways	abolishes	LD	formation	
(31).		
	
In	addition	 the	 turnover	of	glycerophospholipid	acyl	 chains	appears	 to	contribute	 to	LD	
biogenesis.	In	this	context,	members	of	the	large	phospholipase	family	(PLAs)	have	to	be	
considered,	as	these	enzymes	hydrolyze	FA	at	the	sn-2	position	of	phospholipids,	which	
recently	emerged	as	critical	for	LD	homeostasis	(39).	This	family	of	enzymes	represents	a	
very	 heterogeneous	 group	 of	 proteins	 comprising	 of	 more	 than	 30	 proteins	 grouped	
within	6	classes	on	the	basis	of	 their	mode	of	action	and/or	cellular	 location	 (39).	Most	
relevant	for	this	thesis,	members	of	the	calcium	(Ca2	+)-dependent	cytosolic	PLAs	appear	
important	 in	 LD	 formation.	 Utilizing	 pharmacological	 inhibitors	 and	 RNAi	 knockdown	
approaches,	 inhibition	 of	 cytoplasmic	 phospholipase	 A2	 (cPLA2)	 strongly	 reduced	 LD	
formation	 (40-42).	Vice	versa,	overexpression	of	 cPLA2	enhanced	LD	 formation	and	was	
associated	with	Ser505	cPLA2	phosphorylation	 (40).	 Follow-up	studies	 from	Gubern	and	
coworkers	 identified	 c-Jun	 N-terminal	 kinase	 (JNK)	 as	 the	 mitogen	 activated	 protein	
kinase	 (MAPK)	 responsible	 for	 cPLA2	 activation	 in	 LD	 biogenesis	 (43).	 Interestingly,	 the	
role	 of	 cPLA2	 in	 LD	 formation	 does	 not	 seem	 to	 involve	 FA	 delivery	 for	 neutral	 lipid	
synthesis,	but	 the	 formation	of	 lysophospholipids	 in	 the	ER.	This	generation	of	 inverted	
come	 shape	 phospholipids	 within	 the	 ER	 membrane	 would	 create	 positive	 membrane	
curvature,	 a	 process	 that	 would	 favor	 the	 budding	 process	 required	 for	 the	 new	
formation	of	nascent	LD	(40).	
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1.4.1	Lipid	trafficking	into	and	out	of	lipid	droplets	
As	 outlined	 in	 Chapter	 1.4,	 the	 most	 widely	 accepted	 model	 for	 LD	 formation	
hypothesizes	that	LDs	arise	in	the	ER,	through	the	accumulation	of	neutral	lipid	at	specific	
sites	between	the	leaflets	of	the	phospholipid	bilayer.	Upon	reaching	a	critical	mass,	the	
nascent	 LDs	 are	 thought	 to	 bud	 from	 the	 ER	 as	 autonomous	 organelles.	 LD	 formation	
requires	the	coordinated	activity	of	numerous	proteins,	providing	structural	 information	
as	well	as	signaling	and	lipid-modifying	activities	and	has	been	reviewed	in	detail	(10,	29-
31,	44).	In	the	following,	we	will	provide	a	brief	summary,	how	lipids	(FA,	cholesterol)	are	
delivered	and	mobilized	from	LD.	
	
FA	 that	 will	 ultimately	 be	 incorporated	 into	 LDs	 can	 enter	 cells	 either	 through	 the	
endosomal	system	as	lipoprotein	particles,	such	as	LDL,	or	through	FA	transport	proteins	
at	 the	cell	 surface	or	be	synthesized	de	novo.	 Interestingly,	many	of	 the	organelles	 that	
can	 be	 functionally	 linked	 to	 FA	metabolism	 are	 also	 found	 in	 close	 apposition	 to	 LDs,	
including	the	ER,	endosomes,	mitochondria	and	peroxisomes	(10,	29-31,	44).		
	
Given	 the	 complex	 interplay	 of	 lipid-modifying	 enzymes,	 lipid	 intermediates,	 but	 also	
structural	proteins	during	LD	formation	(10)	it	has	been	difficult	to	determine	the	precise	
mechanisms	how	particular	enzymes	contribute	to	neutral	lipid	storage.	Yet,	this	probably	
reflects	the	physiological	significance	of	neutral	 lipid	storage	for	metabolism	in	different	
cell	types	and	tissues.	This	diversity	is	exemplified	by	the	major	long-chain	FAs,	where	at	
least	 eleven	 acyl-CoA	 synthetases	 (ACSs)	 are	 responsible	 for	 their	 activation	 and	
incorporation	into	neutral	lipids	(45).	Likewise,	three	acyltransferase	families	encoded	by	
twelve	genes	catalyze	the	last	synthetic	step	during	the	generation	of	TAGs	(46).	
	
The	activation	of	FA	by	esterification	with	coenzyme	A	 is	 critical	 for	 LD	biogenesis.	This	
requires	ATP	and	is	catalyzed	by	LD-associated	ACS	enzymes.	Indeed,	blocking	ACS	activity	
interferes	with	 TAG	 synthesis	 and	 FA-induced	 LD	 formation	 (47).	 ACS	proteins	not	only	
catalyze	 FA	 activation	 on	 the	 LD	 surface,	 but	 also	 facilitate	 FA	 upake	 and	 act	 as	 FA	
transporters	 (48).	 Further,	 ACS	 proteins	 seem	 to	 interact	 with	 other	 lipid-modifying	
enzymes	 to	 increase	 efficiency	 of	 transferring	 substrates	 from	one	 enzyme	 to	 the	 next	
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(49,	50).	Finally,	ACS	enzymes	also	bind	several	regulatory	proteins	that	determine	LD	size	
and	numbers	(51,	52).	
	
TAG	and	CE	represent	the	most	abundant	neutral	lipids	in	LD,	and	ER-associated	enzymes	
are	commonly	responsible	for	their	generation.	TAG	synthesis	 is	catalyzed	by	glycerol-3-
phosphate	O-acyltransferase,	 1-acylglycerol-3-phosphate	O-acyltransferase,	 phosphatidic	
acid	phosphatase/lipin	enzyme	families.	The	final	step,	the	esterification	of	diacylglycerol	
(DAG)	 into	 TAG	 (53)	 is	 facilitated	by	diglyceride	 acyltransferases	 (DGAT1/2).	Alternative	
mechanisms	 include	 phospholipid:diacylglycerol	O-acyltransferase	 and	 Lro1p,	which	 can	
produce	 TAG	 through	 trans-esterification	 of	 FA	 from	 phospholipids	 (54).	 Finally,	
cholesterol	esterification	 is	mediated	by	acyl-CoA:cholesterol	O-acyltransferases	1	and	2	
in	the	ER.	
	
The	 neutral	 lipid	 in	 these	 droplets	 can	 be	 catabolized	 to	 generate	 free	 FAs	 and	
cholesterol.	The	ultimate	 fate	of	FAs	released	from	LDs	 is	dependent	upon	the	 function	
and	requirements	of	the	cell.	FAs	released	from	LDs	can	be	used	to	generate	ATP	during	
β-oxidation	in	mitochondria	or	peroxisomes	(7,	8),	for	phospholipid	biosynthesis	in	the	ER	
(9),	undergo	efflux	from	the	cell	surface	to	acceptors	such	as	HDL	(10),	or	be	incorporated	
into	lipoproteins	in	the	ER	and	secreted	(2).		
	
The	regulation	of	TAG	and	CE	 lipolysis	 is	as	complex	as	their	synthesis,	 involving	several	
hydrolytic	enzymes	(55).	Adipose	triglyceride	lipase	catalyzes	TAG	hydrolysis	to	DAG	and	
one	 FA	 molecule.	 Next,	 hormone-sensitive	 lipase	 degrades	 DAG	 to	 monoacylglycerol	
(MAG)	 and	 a	 second	 FA	 molecule.	 Finally,	 monoacylglycerol	 lipase	 hydrolyses	 MAG,	
producing	 glycerol	 and	 a	 last	 FA.	 The	 activity	 of	 these	 enzymes	 is	 closely	 linked	 to	
perilipins,	 a	 family	 of	 five	 related	 proteins	with	 a	major	 function	 in	 controlling	 lipolysis	
(10,	29-31).	In	regards	to	CE	hydrolysis,	several	hydrolytic	enzymes	have	been	described,	
with	neutral	cholesteryl	ester	hydrolase	being	the	best	characterized	(56).	
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1.4.2	The	role	of	phospholipases	(PLAs)	in	LD	formation	
As	 outlined	 above	 (1.4),	 and	 not	 directly	 linked	 to	 FA	 and	 cholesterol	
transfer/mobilization	 into	 and	 out	 of	 LD,	 phospholipid	 metabolism	 greatly	 influences	
storage	and	mobilization	of	neutral	 lipids.	Although	phospholipids	do	not	accumulate	 in	
the	core	of	LD,	they	form	the	LD	monolayer	and	their	composition	determines	LD	budding	
and	size.	Phospholipids	are	modulated	by	PLAs	and	these	enzymes	regulate	various	steps	
in	LD	homeostasis,	which	is	briefly	summarized	below.		
	
PLA	enzymes	 are	 a	heterogeneous	 group,	 including	16	different	 groups	 and	 subgroups,	
with	 more	 than	 30	 proteins	 (39),	 all	 of	 which	 hydrolyzing	 FA	 at	 the	 sn-2	 position	 of	
glycerophospholipids.	 They	 can	 be	 grouped	 based	 on	 their	 location	 and	 biochemical	
properties,	 including	 the	 Ca2+-dependent	 cytosolic	 or	 secreted	 PLAs	 and	 the	 Ca2	+-
independent	cytosolic	PLAs.	These	2	PLA	classes	are	believed	to	mobilize	arachidonic	acid	
(AA)	 for	 eicosanoid	 synthesis	 in	 response	 to	 a	 variety	 of	 immunoinflammatory	 stimuli	
(39).	Most	relevant	for	this	thesis	are	the	cPLA2	enzymes.	Six	cPLA2	enzymes	exist	and	are	
classified	 as	 group	 IV	 PLA2s.	 Their	molecular	weight	 ranges	 from	 61–114	kDa	 and	 their	
ability	to	bind	Ca2	+	allows	these	enzymes	to	translocate	to	cellular	membranes.	
	
As	described	in	Chapter	4,	cPLA2α	is	associated	with	LD	and	might	not	only	drive	budding	
events	for	LD	formation	in	the	ER,	but	also	biosynthesis	of	eicosanoids	on	LDs.	Indeed,	5-
lipoxygenase,	 15-lipoxygenase,	 5-lipoxygenase-activating	 protein,	 and	 cyclooxygenase-2	
(57),	which	all	use	AA	as	substrate,	as	well	as	lipin-1	and	Erk1/2,	which	regulate	cPLA2,	AA	
release	 and	 eicosanoid	 production,	 are	 associated	 with	 LDs	 (58).	 Furthermore,	 LD-
associated	PLAs	may	help	 to	 deliver	 FA	 from	membrane	phospholipids	 for	 neutral	 lipid	
synthesis	or	modify	phospholipid-containing	particles	for	internalization.	
	
The	role	of	cPLA2	 in	the	creation	of	positive	ER	membrane	curvature	appears	critical	for	
LD	budding	(see	Chapter	4).	The	underlying	mechanisms	are	still	under	investigation,	but	
it	appears	that	this	process	requires	cPLA2α	phosphorylation.	Depending	on	the	cell	type	
and	 stimuli,	 this	 phosphorylation	 is	 mediated	 by	 various	MAPKs	 or	 JNKs	 (39,	 59).	 This	
involves	 cellular	activation	mediated	by	 stress,	exposure	 to	atherogenic	 lipoproteins,	as	
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well	as	lipid	oversupply	and	viral	 infection	(39).	 In	addition,	Ca2+-independent	PLAs	have	
been	 implicated	 in	 LD	 formation	 during	 cellular	 stress	 and	 the	 integration	 of	 lipid	
metabolism	with	energy	demands	(39).	Other	possible	roles	for	PLAs	include	the	group	of	
secreted	PLAs,	which	alter	the	amount	of	FA	levels	in	plasma,	and	modify	the	surface	of	
circulating	 lipoproteins,	 both	 indirectly	 contributing	 to	 the	 lipids	 that	 enter	 cells	 for	
storage	 (39).	 Finally,	 the	 important	 role	 of	 PLAs	 in	 the	 generation	 of	 AA	 during	
inflammation	needs	to	be	considered,	as	this	impacts	on	lipid	availability	and	delivery	to	
cells	in	various	settings	in	health	and	disease.	
	
1.5	Annexin	A6	-	a	potential	regulator	of	FA	metabolism	
Over	 the	 years,	 Grewal	 and	 colleagues	 have	 intensively	 studied	 Annexin	 A6	 (AnxA6),	 a	
Ca2+	and	membrane	binding	protein	 in	 the	context	of	growth	 factor	 receptor	 signalling,	
cholesterol	transport,	and	more	recently,	 liver	function	and	triglyceride	metabolism	(60-
63).	 Given	 the	 complex	 and	multifunctional	 properties	 of	 this	 protein,	 several	 of	 those	
possibly	 linked	 to	 the	 transport	 of	 lipids	 into	 and	out	 of	 LD,	 as	well	 as	 the	 LD	budding	
process	 itself,	 a	 brief	 summary	 of	 the	 structural,	 membrane	 binding	 and	 functional	
properties	 of	 AnxA6	 is	 needed	 to	 appreciate	 the	 various	 regulatory	 circuits	 that	might	
enable	AnxA6	to	impact	on	neutral	lipid	storage	and	LD	formation.			
	
1.5.1	Structural	and	membrane	binding	properties	of	AnxA6	
AnxA6	 is	 a	member	 of	 annexin	 family,	 all	 of	 which	 are	 a	 dynamic	 and	multifunctional	
family	of	structurally	related	Ca2+	and	membrane-binding	proteins	(63-66).	Annexins	have	
been	 identified	 in	 a	 large	 variety	of	 species	 ranging	 from	protists	 to	higher	 vertebrates	
and	are	classified	into	five	groups	(A–E)	(63,	64).	Group	A	represents	the	12	human	and	
vertebrate	 annexins	 (63,	 64).	 All	 annexins	 are	 composed	 of	 two	 domains:	 a	 conserved	
core	that	is	responsible	for	Ca2+	and	phospholipid-binding,	and	a	variable	N-	terminal	tail	
(63,	64).	
	
AnxA6	is	the	largest	member	of	the	annexin	family	containing	two	annexin	cores	within	a	
single	entity	(63,	64).	The	annexin	core	has	been	described	to	be	highly	helical	and	tightly	
packed	 disk	with	 a	 slight	 curvature	 and	 two	 principal	 sides	 (66,	 67).	 As	 suggested	 in	 a	
review	by	 Enrich	et	 al,	 this	 possibly	 allows	 the	 two	 core	modules	 to	 orient	 themselves	
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relative	to	one	another	in	a	flexible	manner	(64,	68).	In	doing	so	the	molecule	may	bind	
with	its	core	domains	attached	to	either	one	or	two	separate	membranes,	in	a	parallel	or	
anti-parallel	 orientation	 (64,	 68).	 In	 the	 core	 the	 convex	 side	 is	 said	 to	 face	 the	
membrane,	 and	 Ca2+	 type	 II	 (annexin-type)	 binding	 sites	 coordinate	 the	 contact	 of	
carbonyl	and	carboxyl	residues	with	phosphoryl	moieties	of	membrane	phospholipids	(64,	
68,	69).	The	concave	side	on	the	other	hand	points	away	from	the	membrane,	probably	to	
allow	interactions	with	other	proteins	(64,	68-70).	
	
AnxA6	has	been	identified	to	have	an	affinity	to	bind	to	negatively	charged	phospholipids,	
namely	phosphatidylserine	 (PS),	phosphatidylinositol	and	phosphatidic	acid	 (63,	67,	71).	
Earlier	reports	also	identified	affinity	towards	phosphatidylethanolamine	and	to	a	minor	
extend	to	arachidonic	acid,	the	later	being	enriched	in	membrane	rafts	(67,	71).	Further,	
in	 addition	 to	 Ca2+-dependent	 targeting	 of	 AnxA6	 to	 membranes,	 acidic	 pH	 and	
cholesterol	 regulate	 the	 targeting	and	 trafficking	events	 for	AnxA6	 (60,	64,	72,	73).	The	
latter	 is	 relevant	 for	 the	 association	 of	 AnxA6	 with	 cholesterol-rich	 vesicles	 in	 the	
endocytic	 compartment,	 in	 particular	 LDL-enriched	 late	 endosomes.	 Figure	 6	 illustrates	
the	localization	of	six	potential	Ca2+-binding	sites	on	eight	repeats	of	AnxA6	(62,	64).		
	
							 	
Figure	6:	Annexin	A6	protein	 structure	 showing	eight	 repeats	of	AnxA6	 (64).	 The	Ca2+	
binding	 sites,	 the	 linker	 region	 between	 repeats	 4-5,	 several	 phosphorylation	 sites	 at	
serine	 (S),	 tyrosine	 (Y)	 and	 threonine	 (T)	 residues,	 as	well	 as	 the	 VAAEIL	 sequence	 of	 a	
larger	AnxA6	isoform	(Pos	524-529)	generated	by	alternative	splicing	are	shown.	
	
annexin A5 and A10. Crystal structures of AnxA6 in solution and in
associationwith artiﬁcial membranes show that the two coremodules
can probably orient themselves in a ﬂexible manner relative to one
another. This allows the molecule to bind with its core domains
attached to either one membrane or to two separate membranes [4–
7] (Fig. 1). AnxA6 binds to phosphatidylserine (PS), phosphatidyli-
nositol, phosphatidic acid [2], and earlier reports also identiﬁed
afﬁnity towards phosphatidylethanolamine and arachidonic acid [8].
Besides the Ca2+-dependent targeting of AnxA6 to membranes, acidic
pH and cholesterol also regulate the targeting and trafﬁcking events
for this annexin [9–14].
In addition to its membrane binding properties, AnxA6 interacts
with members of the actin cytoskeleton and multiple signaling
proteins. In this review we will make an attempt to characterize the
features that enable AnxA6 to regulate membrane trafﬁcking and
signal transduction: the ability of AnxA6 (1) to regulate caveolin-1
transport, cellul r cholesterol distribution and cPLA2 activity, but als
(2) to organize the cytoskeleton and (3) the formation of multifac-
torial, PKC and HRas containing signaling complexes.
2. AnxA6 and cholesterol homeostasis
Cholesterol is an essential structural constituent of cellular
membranes in eukaryotes. Mammalian cells synthesize their own
cholesterol but also receive exogenous cholesterol through lipopro-
tein uptake. The intracellular routes for the transport of cholesterol—
vesicular and non-vesicular—between membrane compartments are
complex and their regulation is still not fully understood [15,16]. One
important consequence of these various transport routes is that
cholesterol is not uniformly distributed in biological membranes, but
enriched in speciﬁc membrane domains. Certain proteins are found in
these cholesterol-rich domains (membrane rafts), and thus inﬂuence
the functioning of the plasma membrane.
As outlined above, annexins interact with negatively charged
membrane phospholipids in a Ca2+-dependent manner and up to
date, have generally been considered not to bind cholesterol.
However, he mutation l analysis of the annexin core and N-terminal
tail showed that cholesterol can increase the Ca2+-dependent
membrane binding and aggregation of AnxA2. Similarly, AnxA5 and
AnxA6, two annexins with unrelated N-terminal tails but homologous
core domains, also showed a Ca2+-dependent binding to membranes
that was cholesterol-sensitive [17,18]. Smart et al. [19,20] further
challenged the concept of annexins as non-cholesterol binding
proteins and isolated AnxA2 from a cytosolic complex together with
cholesterol and caveolin. Further pointing at the possibility of AnxA2
to interact with cholesterol, AnxA2 translocates to cholesterol-rich
late endosomes in ﬁbroblasts from patients with the cholesterol-
storage disorder Niemann-Pick C [21]. From these studies it was
speculated that cholesterol potentially affects the membrane binding
afﬁnity of other annexins as well, and eventually, their intracellular
localization. Hence, annexins could indeed contribute to cholesterol-
related events in biological membranes through the re-arrangement
of microdomains [17,22].
In support of this hypothesis, we identiﬁed two different pools of
AnxA6 in Chinese Hamster Ovary (CHO) cells. While the majority
(70–80%) of AnxA6 bound to membranes in a Ca2+-dependent
manner, the remaining AnxA6 proteins associated with endosomal
membranes even in the absence of Ca2+. This pool of Ca2+-
independent AnxA6 proteins is strongly inﬂuenced by the amount
and distribution of cholesterol. Cholesterol depletion using methyl-
β-cyclodextrin reduced the membrane binding of Ca2+-independent
AnxA6 proteins to early and late endosomes. Conversely, cholesterol-
loading of l te end somes, using low density lipoproteins (LDL) or
the amphipatic steroid U18666A, stimulated the binding of AnxA6 to
late endosomal membranes [13,14]. Since this translocation of AnxA6
was also observed in drug-induced, cholesterol-rich late endosomes
of NRK ﬁbroblasts, we proposed that cholesterol is a general and
additional modulator f AnxA6-membrane binding and intracellular
distribution. In line with these data, recent studies suggest Ca2+-
independent and cholesterol-, but not cholesteryl acetate, dependent
membrane-binding properties of recombinant AnxA6, implicating
the hydroxyl group of cholesterol in AnxA6-membrane interaction
[11].
Moreover, it is now well-documented that acidic pH induces
conformational changes in AnxA6 leading to increased hydrophobic-
ity, membrane binding afﬁnity [23–25] and high preference for
monolayers containing cholesterol. In model membranes at acidic pH,
the tryptophan 343 residu (Trp343) within the linker region of
AnxA6 seems to be important for the interaction of AnxA6 with
cholesterol in a Ca2+-independent manner [11]. Fig. 2 depicts, in a
simpliﬁed scheme, the steps within intracellular cholesterol transport
pathways and the locations of the various annexins possibly involved.
Fig. 1. Annexin A6 protein structure. (A) The eight repeats of AnxA6 are shown, and the localization of the six potential calcium-binding sites in repeats 1, 2, 4, 5, 6 and 8 are indicated
[177]. The position of phosphorylation sites at S13, Y30, T356 and the larger splice variant (Pos. 524–529) [173] are highlighted. (B) Atomic space-ﬁlling model of bovine AnxA6
[178], where visible Ca2+ (red) and putative phosphorylation sites (yellow) are highlighted. (C) Schematic representation of the amino acid sequences in the N-terminal and the
linker region of human AnxA6. The putative phosphorylation sites within the N-terminus (S13, Y30) and linker (T356) as well as the potential cholesterol-binding site (chol) in the
linker at Trp343 (W343) [11] are indicated.
936 C. Enrich et al. / Biochimica et Biophysica Acta 1813 (2011) 935–947
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Based	 on	 the	 abovementioned	membrane	 binding	 abilities,	 AnxA6	 and	 other	 annexins	
have	been	proposed	to	regulate	membrane	organisation	 (63,	64,	74-76).	However,	only	
recently	 evidence	 has	 emerged	 to	 support	 this	 in	 live	 cells	 and	 organisms:	 (i)	 T-
lymphocytes	from	the	AnxA6	Knockout	(KO)-mice	displayed	reduced	membrane	order	at	
the	plasma	membrane.	(ii)	Membrane	order	and	distribution	of	proteins	in	rafts	and	non-
rafts	 was	 altered	 in	 AnxA6-KO	 mesenchymal	 mouse	 embryo	 fibroblasts	 and	 A431	
squamous	carcinoma	cells	overexpressing	AnxA6	(63,	75-78).	Thus,	high	and	low	levels	of	
AnxA6	may	alter	the	organisation	of	membrane	domains	at	the	plasma	membrane,	and	
possibly	other	cellular	compartments.	However,	if	these	regulatory	features	are	relevant	
for	LD	formation	and	LD	biology,	remain	to	be	identified.		
	
1.5.2	Annexin	A6	and	cholesterol	transport		
LDs	contain	neutral	lipids,	including	cholesteryl	esters,	and	although	all	cellular	routes	for	
cholesterol	 transport	 are	 not	 fully	 understood	(79,	 80),	 the	 major	 pathways	 for	
cholesteryl	 esters	 to	 be	 delivered	 to	 LD	 have	 been	 clarified.	 Most	 cells,	 in	 particular	
hepatocytes,	acquire	cholesterol	through	endocytosis	of	LDL.	After	internalization,	LDL	is	
delivered	 to	 late	 endosomes,	 where	 cholesteryl	 esters	 are	 cleaved	 by	 hydrolases.	 Late	
endosomal	 cholesterol	 is	 then	 delivered	 to	 the	 ER	 for	 re-esterification.	 The	 cholesteryl	
esters	in	the	ER	are	then	deposited	in	LD	that	bud	from	the	ER.			
	
The	Grewal	group	previously	identified	that	cholesterol-loading	of	late	endosomes,	using	
LDL	 or	 the	 amphipatic	 steroid	 U18666A,	 stimulated	 the	 binding	 of	 AnxA6	 to	 this	
compartment	in	a	Ca2+-independent	manner	(81,	82).	This	was	also	observed	in	other	cell	
lines,	 suggesting	 that	 AnxA6	 might	 also	 locate	 to	 LDL-cholesterol	 enriched	 late	
endosomes	in	hepatocytes.	In	line	with	these	data,	others	identified	the	hydroxyl	group	of	
cholesterol	 in	 AnxA6-membrane	 interaction	 to	 facilitate	 Ca2+-independent,	 but	
cholesterol-dependent	membrane-binding	of	recombinant	AnxA6	(83).	
	
In	 follow-up	 studies	 Grewal	 and	 coworkers	 then	 identified	 that	 AnxA6	 overexpression	
caused	late	endosomal	cholesterol	accumulation	reminiscent	of	the	Niemann-Pick	Type	C	
(NPC)	mutation.	This	has	drastic	 consequences	 for	 cellular	 function	 (84),	as	 this	pool	of	
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cholesterol	is	exported	to	various	locations	in	the	cell,	including	the	Golgi	apparatus,	the	
cell	surface,	but	also	to	the	ER	for	cholesterol	esterification.		
	
Hence,	 AnxA6	 upregulation	 triggers	 reduced	 cholesterol	 levels	 in	 the	 Golgi	 and	 the	
plasma	membrane,	which	then	proved	to	be	responsible	for	the	retention	of	caveolin-1	in	
the	Golgi	complex	and	the	reduced	number	of	caveolae	observed	at	the	cell	surface	(84).	
Thus	AnxA6	expression	levels	could	be	a	marker	indicative	of	the	potential	abundance	of	
caveolae	 in	 quite	 a	 lot	 of	 different	 cells	 and	 tissues.	 This	 could	 also	 be	 relevant	 for	 LD	
formation,	as	caveolin	and	caveolae	have	been	linked	to	the	ability	of	cells	to	store	and	
mobilize	lipids	in	LD	in	adipose,	but	also	hepatic	tissues	(33,	85,	86).	
	
Moreover,	 impaired	 cholesterol	 export	 from	 late	 endosomes	 upon	 AnxA6	 upregulation	
not	 only	 interfered	 with	 caveolin-1	 function,	 but	 also	 led	 to	 the	 mislocalization	 and	
inhibition	 of	 several	 soluble	 NSF	 attachment	 protein	receptor	 (SNARE)	 proteins,	 which	
regulate	membrane	budding	and	fusion,	including	SNAP23/syntaxin-4	and	syntaxin-6	(87,	
88).	All	of	these	SNARE	proteins	have	been	implicated	in	LD	biogenesis	and	the	regulation	
of	lipid	transport	into	and	out	of	the	LD,	including	the	liver	(89-91).	
	
Finally,	 yet	 unpublished	 data	 from	 the	 Grewal	 and	 Enrich	 group	 provide	 evidence	 that	
AnxA6	expression	levels	controls	the	transfer	of	cholesterol	from	late	endosomes	to	the	
ER	for	esterification	and	storage	in	LD	(Grewal	and	Enrich,	unpublished).	These	novel,	yet	
unpublished	 findings	 further	 highlight	 an	 important	 link	 between	 AnxA6	 and	 LD	
formation.	
1.5.3	AnxA6	regulates	the	localization	and	activity	of	cPLA2		
As	 described	 above,	 AnxA6	 overexpression	 reduces	 Golgi	 cholesterol,	 which	 inhibits	
caveolin-1	 transport	 from	the	Golgi	 to	 the	cell	 surface.	The	 regulation	of	 this	process	 is	
complex,	 but	 cPLA2	 is	 part	 of	 the	machinery	 that	 controls	 secretory	 routes	 emanating	
from	the	Golgi	(92).	
	
The	 ability	 of	 annexins	 to	 inhibit	 secreted	 members	 of	 the	 PLA2	family	 is	 well	 known,	
possibly	due	to	annexins	and	PLA2	competing	for	Ca2+	and	phospholipids	(93).	Only	cPLA2α	
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out	 of	 the	 Ca2+-sensitive	 cPLA2	members	 binds	 to	 the	 Golgi	 upon	 Ca2+	 stimulation	 to	
release	arachidonic	acid	from	the	sn-2	position	in	phospholipids	(94).	Elevated	cholesterol	
levels	 trigger	 cPLA2	 translocation	 to	Golgi	membranes	 (95-97)	 to	drive	 the	 formation	of	
positive	membrane	curvature,	a	requirement	for	Golgi	vesiculation.	Interestingly,	reduced	
Golgi-cholesterol	levels	in	AnxA6	expressing	cells	inhibited	association	of	cPLA2α with	the	
Golgi.	These	findings	would	explain	reduced	vesiculation	of	caveolin-1	containing	vesicles	
along	 the	 secretory	 pathway	 to	 the	 cell	 surface.	 It	 is	 tempting	 to	 speculate	 that	 the	
cholesterol	phenotype	caused	by	AnxA6	up	regulation	would	also	 impact	on	the	role	of	
cPLA2	in	LD	formation.		
	
1.5.4	The	scaffolding	function	of	AnxA6		
Besides	 the	 ability	 of	 AnxA6	 to	 regulate	 membrane	 organization	 and	 cholesterol	
distribution,	 AnxA6	 interacts	 with	 multiple	 members	 of	 the	 actin	 cytoskeleton	 and	
signaling	 proteins.	 This	 scaffolding	 function	 of	 AnxA6	 probably	 creates	 multiprotein	
complexes	 that	 can	 serve	 as	 compartment-specific	 signaling	 platforms	 in	 various	
membrane	microdomains.	Over	the	years,	the	Grewal	group	particularly	focused	on	the	
scaffolding	 role	 of	 AnxA6	 for	 two	 proteins	 that	 are	 central	 to	 signal	 transduction	
pathways	in	various	cellular	processes.	It	would	go	beyond	the	scope	of	this	thesis	to	list	
all	AnxA6	interaction	partners,	which	can	be	found	in	previous	reviews	from	Grewal	and	
and	coworkers	(67,	98-100).	First,	high	levels	of	AnxA6	serve	as	a	docking	site	for	PKCα	at	
the	plasma	membrane.	This	 increases	the	ability	of	PKCα	to	 interact	with	the	epidermal	
growth	 factor	 receptor	and	phosphorylate	 the	Thr654	residue	of	EGFR,	 leading	 to	EGFR	
inactivation	(62,	76,	78,	100-102).	It	is	tempting	to	speculate	that	the	ability	of	AnxA6	to	
recruit	 PKCα	 is	 also	 relevant	 for	 other	 biological	 processes.	 Indeed,	many	 reports	 have	
linked	PKCα	with	FA	and	TAG	metabolism	(76,	78,	101-103).		
	
Very	 similar	 to	 the	 recruitment	 process	 described	 above,	 AnxA6	 also	 facilitates	 the	
membrane	 association	 of	 the	 GTPase	 activating	 protein	 p120GAP	 (104-106),	 which	
enables	 p120GAP	 to	 bind	 and	 inactivate	 members	 of	 the	 Ras	 protein	 family	 (60).	
Consequently,	AnxA6	upregulation	 is	 associated	with	 reduced	activity	 of	 the	Ras/MAPK	
pathway	in	many	different	cell	types.	In	contrast,	AnxA6	depletion	is	often	accompanied	
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by	 elevated	 Ras	 activity,	 and	 enhanced	MAPK	 signaling,	 overall	 implicating	 AnxA6	 as	 a	
tumor	suppressor(107).	Of	note,	this	signaling	pathway	is	not	only	relevant	in	oncogenic	
settings,	 but	 cPLA2	is	 also	 phosphorylated	 by	 mitogen-activated	 protein	 kinase	 (MAPK)	
extracellular	signal-regulated	kinase	1/2	(ERK1/2)	at	Ser505,	which	increases	its	enzymatic	
activity	 (108-110).	 This	 phosphorylation	 seems	 to	 enable	 cPLA2	 membrane	 association	
and	AA	release	(111).	Since	AnxA6	inhibits	Erk1/2	signaling	kinases	(98,	99,	104),	this	may	
also	impact	on	the	ability	of	cPLA2	to	promote	LD	formation. 
	
1.5.5	Potential	roles	of	AnxA6	in	hepatocytes	and	adipocytes		
In	the	liver	AnxA6	constitutes	0.25%	of	total	protein	mass.	Electron	microscopy	identified	
AnxA6	 in	 the	apical	 endocytic	 compartment	 (112)	 and	 subcellular	 fractionation	 showed	
AnxA6	in	purified	endosomes	from	rat	liver	(113).	Hence	AnxA6	is	considered	a	marker	for	
endosomes	(114).	In	addition,	earlier	studies	identified	AnxA6	at	the	plasma	membrane	in	
sinusoidal	 and	 canalicular	 domains	 (114).	 In	 all	 these	 locations,	 AnxA6	 is	 probably	
involved	 in	 the	 regulation	 of	 various	 membrane	 transport	 events	 connecting	 the	
endocytic	 compartment	with	 the	 cell	 surface.	 In	 the	WIF-B	 cell	 line,	which	 is	 polarized,	
enabling	 studies	 on	 hepatocyte	 polarity,	 a	 pool	 of	 AnxA6	 proteins	 was	 found	 on	
lysosomes	(115)	and	associated	with	Golgi	membranes	(113,	115).	
	
Recently	Grewal	and	coworkers	examined	hepatic	AnxA6	levels	in	pathological	conditions	
that	are	associated	with	 liver	dysfunction	and	 liver	 injury	 (116).	 It	 is	 generally	 assumed	
that	AnxA6	 is	 constitutively	expressed	and	even	 in	 the	 fatty	 liver	of	mice	 fed	a	high-fat	
diet,	 in	 ob/ob	 and	 db/db	 animals	 as	 well	 as	 murine	 nonalcoholic	 steatohepatitis	 and	
human	 liver	 fibrosis	 and	 human	 fatty	 liver,	 AnxA6	 protein	 levels	 appeared	 unchanged.	
However,	AnxA6	protein	levels	were	substantially	reduced	in	hepatic	tumors,	while	AnxA6	
mRNA	was	 upregulated,	 indicating	 post-transcriptional	 regulation	 of	 AnxA6	 expression.	
Although	cholesteryl	esters	were	elevated	in	tumor	samples,	a	significant	correlation	with	
AnxA6	 levels	 was	 not	 apparent.	 As	 NAFLD	 can	 ultimately	 lead	 to	 hepatocellular	
carcinoma,	 these	 studies	 are	 the	 first	 findings	 that	 liver	 dysfunction	 is	 associated	with	
changes	in	AnxA6	levels.		
	
 
 
18 
Finally,	 a	 recent	 study	 in	 adipocytes	 provided	 evidence	 for	 AnxA6	 modulating	 TG	
metabolism	 (117).	 AnxA6	 depletion	 in	 3T3-L1	 pre-adipocytes	 led	 to	 downregulation	 of	
lipolysis,	 causing	 elevated	 triglyceride	 storage.	 Expression	 analysis	 identified	 elevated	
AnxA6	protein	levels	in	white	adipose	tissues	of	obese	mice,	indicating	that	at	least	in	fat	
tissue,	triglyceride	accumulation	is	linked	to	AnxA6	expression	levels.	
	
1.5.6	Insights	on	AnxA6	functions	in	vivo	from	the	AnxA6	knockout	mice	
Over	 the	 years,	 and	 akin	 to	 research	 on	 other	 annexins,	 in	 vitro	 and	 gain-	 and	 loss-	 of	
function	studies	in	cell	culture	identified	a	plethora	of	functions	for	AnxA6.	Some	of	those	
are	 described	 in	 the	 previous	 chapter	 and	 are	 generally	 linked	 to	 AnxA6	 binding	 to	
membranes	in	a	dynamic	and	reversible	manner.	However,	each	cell	commonly	expresses	
multiple	 annexins,	 often	 in	 various	 locations	 and	 numerous	 interaction	 partners.	
Furthermore,	 the	 strong	 overlap	 of	 AnxA6	 and	 other	 annexins	 in	 terms	 of	 membrane	
association,	localization	and	interaction	partners	have	complicated	identification	of	their	
precise	 functions	 in	vivo.	 Interestingly,	depletion	of	one	or	even	two	annexins	 in	mouse	
models	did	not	result	in	abnormal	development	or	affect	vialbility,	suggesting	redundancy	
within	 annexins	 (116).	 However,	 in	 recent	 years,	 exposure	 of	 Anx	 KO-mice	 to	 stress	
conditions	 revealed	 very	 specific	 mechanisms	 specific	 for	 individual	 annexins,	 often	
supporting	the	models	developed	from	in	vitro	and	cell	culture	studies.		
	
The	AnxA6-KO	mice	has	been	extensively	reviewed	by	our	research	group	recently	(116,	
118)	 and	 in	 the	 following	 the	major	 findings	will	 be	 briefly	 summarized.	Mice	 express	
high	AnxA6	levels	in	almost	all	tissues.	First	efforts	to	study	AnxA6	in	vivo	used	transgenic	
overexpression	 in	 the	 heart,	 identifying	 enlarged	 dilated	 hearts	 and	 acute	 diffuse	
myocarditis	(119).	Despite	this	phenotype	in	vivo	upon	AnxA6	overexpression,	AnxA6	KO-
mice	 generated	 by	 the	Moss	 group	 appeared	 normal	 (120)	 and	 clearly	 questioned	 the	
various	AnxA6	functions	derived	from	cultured	cells.	Even	the	generation	of	mice	lacking	
two	annexins,	AnxA5	and	AnxA6	(121)	did	not	show	obvious	abnormalities.	However,	in	
later	 studies,	 reduced	growth	plate	 length	and	number	of	 chondrocytes	documented	a	
skeletal	phenotype	of	AnxA6	KO-newborns	and	defective	PKCα	membrane	translocation	
and	activity	was	proposed	as	 the	underlying	defect	 (121).	 In	 line	with	 this,	 the	Grewal	
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group	and	Moss	 et	 al.	determined	 that	AnxA6	overexpression	 reduced	A431	 xenograft	
growth,	most	 likely	due	to	 increased	PKCa-mediated	EGFR	 inhibition	(122)	 (Grewal	and	
Hoque,	unpublished	data).	Later	studies	employed	a	physiological	challenge	to	address	if	
lack	 of	 AnxA6	 could	 cause	 defective	 biological	 responses.	 Indeed,	 mimicking	
osteoarthritis,	knee	cartilage	destruction	was	markedly	reduced	in	AnxA6	KO-mice	(123).	
Grewal	 and	 coworkers	 recently	 identified	 that	 AnxA6	 depletion	 in	 vivo	 perturbed	 the	
organisation	of	cholesterol-rich	domains	required	for	appropriate	IL-2	receptor	signaling	
during	 immune	 response	 (124).	 AnxA6-deficient	 mice	 also	 display	 reduced	 bacterial	
clearance	 after	 oral	 challenge	 with	 Citrobacter	 rodentium,	 indicating	 a	 higher	
susceptibility	to	infection	(116).		
	
Besides	 these	 findings,	 Grewal	 and	 collaborators	 have	 commenced	 to	 study	 disease	
settings	 with	 a	 focus	 on	 liver	 function.	 Most	 strikingly,	 after	 partial	 hepatectomy	
compromised	 liver	 regeneration	 led	 to	 strongly	 reduced	survival	 rate	 in	 the	AnxA6	KO-
mice	(123).	Reduced	LD	formation	and	steatosis,	prolonged	hypoglycaemia	and	impaired	
gluconeogenesis	 were	 observed,	 as	 AnxA6-KO	 hepatocytes	 could	 not	 produce	 glucose	
from	 alanine,	 a	 major	 substrate	 for	 hepatic	 gluconeogenesis	 after	 hepatectomy	 or	
fasting.	 Furthermore,	 after	high-fat	diet	 feeding,	when	mice	eventually	develop	a	 fatty	
liver	 and	 insulin	 resistance,	 AnxA6	 KO-mice	 were	 unable	 to	 downregulate	 hepatic	
gluconeogenesis	and	lower	blood	glucose	levels.	As	glucose	metabolism	is	closely	linked	
with	triglyceride	metabolism,	one	can	speculate	that	the	ability	to	store	neutral	lipids	in	
AnxA6-KO-mice	could	also	be	affected.	Indeed,	the	number	and	size	of	LD	in	the	liver	of	
AnxA6-KO	mice	 was	 strongly	 reduced,	 which	 was	 associated	 with	 a	 reduced	 ability	 of	
AnxA6-KO	hepatocytes	to	form	LD	upon	OA	loading	(118).		
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Figure	7:	The	multiple	locations	of	AnxA6	(62).	Trafficking	along	the	endocytic	pathway	is	
indicated	by	thin	blue	arrows.	At	the	plasma	membrane	(PM),	the	first	step	in	endocytosis	
is	 the	 formation	 of	 clathrin	 coated	 pits	 (CCPs).	 CCP	 vesicles	 are	 delivered	 to	 early	
endosomes	(EE),	from	where	cargo	is	targeted	to	late	endosomes	(LE)	and	then	lysosomes	
(Lys)	 for	 degradation.	 Receptors	 can	 be	 recycled	 via	 recycling	 endosomes	 (RE).	 AnxA6	
(green)	 is	 found	 in	 the	 cytosol	 and	 translocates	 to	 the	 PM,	 EE,	 LE,	 caveolae/lipid	 rafts	
(thick	blue	arrows),	but	also	lipid	droplets	(red	arrow).	AnxA6	is	very	dynamic	with	rapid	
changes	 in	 its	 localisation.	 AnxA6	 translocates	 to	 the	 PM	 and	 lipid	 rafts	 upon	
Ca2+elevation,	 where	 it	 is	 thought	 to	 interact	 with	 EGFR	 and	 impact	 on	 signal	
transduction.	There	is	also	cholesterol	(Chol)	 -inducible	translocation	to	LE,	where	AnxA6	
affects	cholesterol	export.	The	different	locations	are	also	listed	in	the	Table	1	(below).	
	
Location	 	 	 	 Ca2+		 	 Cholesterol	 	 pH	
Plasma	membrane		 	 	 +	 	 	 ?	 	 -	
Early	endosomes	 	 	 +	 	 	 ?	 	 -	
Late	endosomes	 	 	 +	 	 	 +	 	 +	
Caveolae,	lipid	rafts	 	 	 +	 	 	 (+)	 	 -	
Lipid	droplets	 	 	 													?	 	 	 ?	 	 -	
Table	1:	The	multiple	cellular	locations	of	Annexin	A6.	The	stimuli	(Ca2+,	Cholesterol,	pH)	
that	 trigger	 translocation	of	AnxA6	 to	a	 specific	 cellular	 location	are	 listed.	 It	 should	be	
noted	that	protein-protein	interactions	may	also	contribute	to	the	recruitment	of	AnxA6	to	
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specific	cellular	compartments	(44,	61,	62,	65,	125,	126).	
	
1.6	Aims	and	Hypothesis	
The	 predominant	 locations	 of	 AnxA6	 inside	 cells	 include	 the	 plasma	 membrane	 and	
endosomes	(60,	61,	127).	In	addition,	AnxA6	has	also	been	found	in	mitochondria,	and	in	
secretory	 vesicles	 (63,	 74,	 128-130).	 As	 outlined	 in	 the	 previous	 sections,	 in	 these	
locations,	 interactions	 with	 numerous	 proteins	 enable	 AnxA6	 to	 modulate	 endo-	 and	
exocytosis,	 membrane	 microdomains,	 cell	 signalling,	 cholesterol	 transport,	 actin	 re-
arrangements	and	phospholipase	activity.	These	multiple	activities	have	placed	AnxA6	in	
regulatory	 circuits	 relevant	 for	 cell	 growth,	 apoptosis,	 motility,	 development,	
inflammatory	response	(62,	64,	98,	131),	membrane	repair	(132,	133)	and	viral	infection	
(134,	135).	
	
More	 recently,	 Grewal	 and	 colleagues	 also	 linked	 AnxA6	 with	 triglyceride	 lipolysis	 in	
adipocytes	 (117),	 and	 identified	 several	 functions	 in	 the	 AnxA6-KO	 mice	 suggesting	 a	
prominent	function	for	AnxA6	in	hepatic	FA	and	triglyceride	metabolism	(123).	In	a	recent	
study	 (118),	 fluorescence	 microscopy	 co-localized	 AnxA6	 with	 LD	 markers	 in	 HuH7	
hepatocytes,	 suggesting	 AnxA6	 to	 bind	 LDs.	 Furthermore,	 electron	 microscopy	 of	 liver	
sections	revealed	significantly	lower	LD	numbers	in	Anx6-KO	mice	compared	to	controls.	
Moreover,	quantification	of	lipid	staining	by	fluorescence	microscopy	and	flow	cytometry	
identified	AnxA6	up-	or	downregulation	to	increased	or	decrease	the	number	and	size	of	
LD	upon	OA	loading,	respectively.	Studies	utilizing	pharmacological	cPLA2α	inhibitors	did	
reduce	LD	formation	in	controls,	but	not	in	AnxA6-depleted	HuH7	hepatocytes	(118).		
	
Based	on	these	findings,	we	hypothesized	a	novel	regulatory	role	of	hepatic	AnxA6	in	LD	
formation,	 possibly	 involving	 cPLA2α-dependent	 pathways.	 The	 purpose	 of	 this	 project	
was	 to	 substantiate	 the	 findings	 described	 above.	 More	 specifically,	 the	 aims	 of	 this	
project	were:	
1. To	 support	 findings	 from	 the	 co-localization	 studies	 and	 identify	 AnxA6	 in	 LD	
fractions	isolated	from	liver	tissue.			
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2. To	 validate	 increased	 triglyceride	 accumulation	 in	 AnxA6	 overexpressing	 HuH7	
hepatocytes	 that	 are	 based	 on	 fluorescence	microscopy	 and	 flow	 cytometry	 by	
determining	triglyceride	levels	from	isolated	LD	fractions.	
3. To	examine	 if	OA	 loading	or	 lipid-modifying	conditions	alter	AnxA6	expression	 in	
primary	hepatocytes	and	hepatocyte	cell	lines.	
4. To	determine	hepatic	AnxA6	expression	in	mouse	models	of	insulin	resistance	and	
obesity.	
5. To	examine	cPLA2	phosphorylation	in	HuH7	cells	upon	OA	loading.	
	
Altogether	 this	 project	 will	 contribute	 to	 shed	 new	 insight	 on	 the	 role	 of	 AnxA6	 in	
triglyceride	 accumulation	 and	 LD	 biology	 in	 hepatocytes.	 Ultimately,	 this	 will	 serve	 to	
provide	 further	 mechanistic	 insight	 how	 AnxA6	 contributes	 to	 lipid	 homeostasis	 in	
physiological	conditions	reminiscent	of	disease	states	such	as	NAFLD	and	MS.		
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2.	Materials	and	Methods	
2.1	Reagents	and	Antibodies:		
Dulbecco's	Modified	Eagle	Medium	(DMEM),	puromycin,	oleic	acid	 (OA),	FA-free	bovine	
serum	 albumin	 (BSA),	 Wy-14643	 were	 from	 Sigma.	 Methyl	 arachidonyl	
fluorophosphonate	 (MAFP)	 was	 from	 BIOMOL	 Research	 Laboratories.	 SDS-PAGE	
molecular	weight	markers	were	from	Fermentas.	Rabbit	polyclonal	anti-β-actin	was	from	
BD	 Transduction	 Laboratories.	 Antibodies	 against	 adipose	 triglyceride	 lipase	 (ATGL),	
cytochrome	C	 (Cyt	C),	Erp72,	NA/K-ATPase,	glyceraldehyde	3-phosphate	dehydrogenase	
(GAPDH),	 Rab	 11,	 Phospho-Ser505	 and	 total	 cPLA2α,	 horseradish	 peroxidase-labeled	
secondary	 goat	 anti-mouse	 and	 goat	 anti-rabbit	 antibodies	 were	 from	 Cell	 Signaling.	
Polyclonal	rabbit	anti-AnxA6	was	prepared	in	our	laboratories	(81,	82).	HuH7,	AML12	cell	
lines	 were	 from	 the	 American	 Type	 Culture	 Collection	 (ATCC,	 Manassas,	 VA,	 USA).	
Lipoprotein-deficient	serum	(LPDS)	and	LDL	was	kindly	provided	by	Prof.	Kerry-Anne	Rye	
(UNSW,	Sydney,	Australia).	
	
2.1.1	OA-BSA	complex	formation	
To	 avoid	 the	 toxic	 effects	 of	 free	 fatty	 acids	 on	 cells,	 incubation	 of	 cells	 with	 BSA-
complexed	OA	is	required	to	study	LD	formation.	Complexed	OA	was	prepared	according	
to	 the	method	outlined	by	Brasaemle	and	Wolins	 (25).	Briefly,	OA	was	complexed	with	
FA-free	BSA	 in	a	6:1	molar	ratio.	The	BSA	was	first	dissolved	 in	0.1	M	Tris.HCL	(pH	8.0),	
then	OA	was	added	and	the	solution	was	mixed	using	a	platform	shaker	for	1	h	at	room	
temperature	until	the	solution	was	clear	(indicating	complete	complexation).	The	OA-BSA	
complex	was	 filter-sterilized	 (0.2	µm),	 stored	 at	 -20°C	 and	 diluted	 in	media	 to	working	
concentration	before	addition	to	cells.			
	
2.1.2	LPDS	and	LDL	preparation	and	treatment	
LPDS	and	LDL	were	kindly	provided	by	Prof.	Kerry-Anne	Rye	(UNSW,	Sydney,	Australia).	In	
brief,	human	blood	was	collected	into	EDTA-Na2	tubes	(final	concentration	1	mg/ml)	and	
placed	immediately	on	ice.	Plasma	was	isolated	at	4°C	by	centrifugation	at	3,000	rpm	for	
15	 min.	 LDL	 (density	 1.025–1.050	 g/ml)	 was	 prepared	 from	 plasma	 by	 two	 sequential	
density	 gradient	 ultracentrifugations	 in	 KBr	 gradients	 (136).	 LPDS	 was	 isolated	 by	
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ultracentrifugation	as	 the	 fraction	of	d	>	1.25	 g/ml.	All	 the	ultra-centrifugal	 procedures	
were	carried	out	at	4°C	at	a	speed	of	100,000	rpm	for	16	h,	using	a	Beckman	(Fullerton,	
CA)	TLA-100.4	rotor	in	a	Beckman	TL-100	tabletop	ultracentrifuge.	LDL	was	stored	in	KBr	
until	needed	 for	experiments.	Before	use,	LDL	was	dialyzed	extensively	against	TBS	and	
stored	at	4°C.	LDL	was	stored	in	dark-coloured	tubes	to	minimize	exposure	to	light.	LPDS	
was	extensively	dialysed	against	PBS,	filter	sterilized	and	stored	at	-20°C	until	use.	
	
2.1.3	Antibodies		
Antibodies	 used	 in	 this	 study	 are	 summarised	 in	 Table	 2.	 All	 antibodies	 used	 are	
commercially	 available,	 with	 the	 exception	 of	 the	 in-house	 rabbit	 polyclonal	 antibody	
against	 Annexin	 A6	 (raised	 against	 purified	 recombinant	 glutathione-s-transferase-
annexin	 A6	 fusion	 protein)	 (126).	 For	 western	 blotting	 (see	 below),	 antibodies	 were	
prepared	in	PBS-Tween	(0.1	%	Tween-20,	ThermoFisher,Waltham,	MA,	USA)	containing	1	
%	(w/v)	skim	milk	or	1	%	(w/v)	BSA.	Dilutions	are	given	in	Table	1.		
Antibodies	 Host	 Dilution	 Manufacturer	 Cat.	No.	
Primary	 	 	 	 	
P-cPLA2a	
(Ser505)	
Rabbit	 1:1000	 Cell	Signaling	 2831	
cPLA2a	 Rabbit	 1:1000	 Cell	Signaling	 2832	
b-Actin	 Rabbit	 1:1000	 Cell	Signaling	 4967	
Annexin	A6	 Rabbit	 1:1000	 Grewal	Group	(82)		 	
ADRP	
ATGL	
Erp72	
CytC	
Na/K-ATPase	
Rab11	
Rabbit	
Rabbit	
Rabbit	
Rabbit	
Rabbit	
Rabbit	
1:1000	
1:1000	
1:1000	
1:1000	
1:1000	
1:1000	
Abcam	
Cell	Signaling	
Cell	Signaling	
Cell	Signaling	
Cell	Signaling	
Cell	Signaling	
Ab52355	
2138	
5033	
4280	
3010	
5589	
Secondary		 	 	 	 	
Anti-rabbit	 Goat	 1:5000	 Cell	Signaling	 7074	
Table	 2:	 Antibodies	 used	 in	 this	 study.	 The	 host,	 dilution	 in	 western	 blotting,	
manufacturer	and	catalogue	number	is	given.		
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2.2	Cell	Culture	and	treatments		
2.2.1	Cell	culture	
Cell	 culture	was	performed	as	per	details	 outlined	below.	 Tissue	 culture	 treated	plastic	
ware	was	from	Corning	Incorporated	Life	Sciences,	Lowell,	MA,	USA.		
	
2.2.1.i	HuH7	cells	
HuH7	cells	are	adherent	cells,	were	grown	 in	72	cm2	 flasks	and	cultures	were	generally	
discarded	 after	 passage	 30.	 HuH7	 wild	 type	 (WT)	 and	 HuH7	 with	 stable	 AnxA6	 over-
expression	(HuH7-A6)	or	knock-down	(A6-KD)	(see	below),	were	all	maintained	in	DMEM	
(low	glucose	with	Glutamax,	GIBCO	by	Life	Technologies,	Carlsbad,	CA,	USA),	L-glutamine	
2	mM,	supplemented	with	10	%	(v/v)	fetal	calf	serum	(FCS,	HycloneÒ	by	Thermo	Fisher	
Scientific,	Waltham,	MA,	USA),	penicillin	(100	units/mL)	and	streptomycin	(100	µg/mL)	at	
37°C,	5	%	CO2.	For	experiments,	cells	were	seeded	at	200,000	cells/well	 in	6-well	plates	
unless	otherwise	specified.		
	
2.2.1.ii	HuH7	stably	overexpressing	AnxA6	(HuH7-A6)		
The	generation	of	the	HuH7	overexpressing	cell	line	stably	overexpressing	AnxA6	(HuH7-
A6)	has	been	described	previously.	In	brief,	HuH7	cells	were	transfected	with	pcDNAanx6	
(82)	 using	 LipofectamineÒ	 2000.	 The	 stably	 transfected	 cells	 were	 selected	 in	 the	
presence	of	1	mg/ml	G418	(Merck	Millipore,	Billerica,	MA,	USA).	G418-containing	media	
was	 refreshed	 every	 2-3	 days	 and	 the	 cells	 were	 passaged	 as	 necessary.	 Transfections	
were	carried	out	in	6-well	plates,	with	1.5	µg	DNA	and	4	µL	LipofectamineÒ	reagent	per	
well,	 each	 diluted	 in	 250	µL	Opti-MEMÒ	 (Invitrogen).	 Cells	were	 incubated	 in	 the	 final	
transfection	mix	for	4-6	h	before	being	washed	with	PBS	and	incubation	with	fresh	culture	
medium	for	further	16-48	h.	Cells	were	kept	under	selection	for	2	weeks,	G418-resistant	
and	 AnxA6-overexpressing	 HuH7	 cells	 were	 identified	 and	 examined	 for	 protein	
expression	via	western	blotting	(87).		
	
2.2.1.iii	HuH7	cells	with	stable	AnxA6	knockdown	(HuH7-A6KD)	
HuH7	cells	with	stable	AnxA6	knockdown	(HuH7-A6KD)	were	generated	after	transfection	
with	1.5	μg	SureSilencing	Short	hairpin	RNA	(shRNA)	plasmid,	obtained	from	SuperArray	
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Biosciences	 (Frederick,	 MD,	 USA)	 targeting	 human	 AnxA6	 at	 position	 352–372	 (5′-
gcaaggacctcattgctgatt-3′)	 and	 LipofectamineÒ	 RNAiMAX	 Invitrogen.	 Transfections	 were	
carried	out	according	to	manufacturer’s	instructions	and	optimized	for	conditions	such	as	
reagent	and	plasmid	concentration.	For	stable	knockdown,	1.5	µg/mL	puromycin	(Sigma-
Aldrich)	was	 added	 48	 h	 post	 transfection.	 Puromycin	 containing	media	was	 refreshed	
every	2-3	days	and	the	cells	were	passaged	as	necessary.	Cells	were	kept	under	selection	
for	 2	weeks	 and	 then	 puromyin-resistant	 and	 AnxA6-depleted	 colonies	were	 identified	
(87)	and	examined	for	protein	expression	via	western	blotting	(see	2.8).	
		
2.2.1.iv	AML12	mouse	hepatocytes	
AML12	 were	 cultured	 in	 DMEM/Ham’s	 F12	 (1/1)	 with	 10	 %	 FCS	 and	 antibiotics	 as	
described	above.		
	
2.2.2	Treatments	
2.2.2.i	Oleic	acid	treatment	to	induce	LD	formation		
To	 promote	 LD	 formation,	 1-2	 x	 106	 cells	 were	 incubated	 for	 24	 h	 with	 0.6	 mM	 OA	
complexed	with	FA-free	BSA	 (Research	Organics,	Cleveland,	OH,	USA)	 in	normal	growth	
media	 as	 described	 (25,	 129).	 For	 the	 experiments	 examining	 FA	 export	 from	 LD	 (also	
termed	 ‘recovery’),	OA-containing	media	was	removed	and	the	cells	were	washed	once	
with	PBS	before	addition	of	DMEM/10	%	FCS	for	a	further	48	h	to	facilitate	exit	of	lipids	
from	LDs.		
	
2.2.2.ii	MAFP	treatments		
For	experiments	involving	the	inhibition	of	cPLA2α,	cells	were	pre-incubated	with	10	μM	
MAFP	for	20	min	(84)	prior	to	addition	of	0.6	mM	OA.	Cells	were	then	 incubated	 in	the	
presence	of	MAFP	and	OA	for	additional	6	h.		
	
2.2.2.iii	LPDS,	LDL,	Wy-14643	treatments	and	serum	starvation	
1-2	x	106	cells/well	were	seeded	into	a	6-well	plate	and	left	to	settle	over	night.	Cells	were	
then	incubated	overnight	in	growth	media	supplemented	with	10	%	(v/v)	LPDS	at	37°C,	5	
%	CO2.	Cells	were	then	treated	with	LDL	(50	µg/mL)	overnight,	respectively.	For	incubation	
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with	PPARa-agonists	(Wy-14643)	or	serum	starvation,	cells	were	plated	and	left	to	settle	
overnight,	followed	by	24	h	treatment	with	20	µm	Wy14643	or	0.1	%	FCS.	Following	these	
incubations,	cells	were	lysed	for	western	blot	analysis	(see	2.8).	
	
2.3	RNA	isolation,	cDNA	synthesis	and	quantitative	real-time	PCR	
To	analyze	mRNA	expression,	cells	were	treated	±	0.6	mM	OA,	 lysed	and	total	RNA	was	
isolated	 in	 collaboration	 with	 Prof.	 Katia	 Monastyrskaya	 (Bern,	 Switzerland)	 using	 the	
mirVana	RNA	 isolation	kit	 (Ambion).	The	RNA	purity	and	concentration	was	determined	
using	the	NanoDrop	ND-1000	(PeqLab).	Subsequent	cDNA	synthesis	was	performed	with	
500	ng	 of	 RNA	 using	 the	 High	 Capacity	 cDNA	 Reverse	 Transcription	 Kit	 (Applied	
Biosystems)	 with	 random	 hexamer	 primers	 following	 the	 manufacturer's	 instructions.	
Relative	mRNA	levels	were	determined	by	quantitative	real-time	PCR	 in	triplicates	using	
SYBR-Green	and	the	7900HT	Fast	Real-time	PCR	System	(Applied	Biosystems)	as	described	
previously	 (137).	 Exon	 junction-spanning	 primers	 were	 designed	 by	 using	 PrimerBLAST	
software	and	synthesized	by	Microsynth	(Switzerland).	The	following	primer	pairs	for	the	
human	 AnxA2,	 AnxA6	 and	 28s	 rRNA	 were	 used:	 AnxA2:	 forward	 5’-
AACTTTGATGCTGAGCGGGA-3‘	(nt	221-240),	reverse	5’-TGCTGCGGTTGGTCAAAATG-3’	(nt	
301-320);	AnxA6:	 forward	5’-TGGCTGCTGAGATCTTGGAAA-3’	 (nt	1679-1699),	 reverse	5’-
GATCGTCATGAAACGTGTCTCC-3’	 	 (nt	 1734-1755);	 28s	 rRNA:	 forward	 5’-
GTTGTTGCCATGGTAATCCTGCTCAGTAC-3’	 (nt	 4535-4564),	 reverse	 5’-
TCTGACTTAGAGGCGTTCAGTCATAATCC-3’	 (nt	 4638-4667).	 Gene	 of	 interest	 cycle	
threshold	(Ct)	values	were	normalized	to	28s	rRNA	housekeeper	levels.	The	end	products	
of	all	PCR	reactions	were	analyzed	on	4	%	low	melting	point	agarose	gels	to	validate	the	
correct	 fragment	 size.	 The	 relative	 expression	 of	 AnxA2	 and	 AnxA6	 was	 calculated	 by	
correlating	the	normalised	Ct	values	of	OA-incubated	samples	to	the	untreated	controls	
(ΔΔCt	method).	
	
2.4	Preparation	of	whole	cell	lysates		
To	prepare	whole	cell	 lysates	 (WCL),	cells	were	placed	on	 ice	and	washed	twice	quickly	
with	 ice-cold	 PBS.	 Cells	 were	 scraped	 in	 ice-cold	 lysis	 buffer	 with	 protease	 and	
phosphatase	inhibitors	(20	mM	Tris-HCL,	pH	7.5,	2	mM	EDTA,	100	mM	NaCl,	5	mM	MgCl2,	
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1	%	Triton	X-100,	5	mM	NaF,	10	%	(v/v)	glycerol,	0.5	%	(v/v)	2	mercaptoethanol,	0.1	mM	
Na3VO4,	 1	 mM	 phenylmethylsulfonyl	 fluoride	 (PMSF),	 5	µg/mL	 leupeptin	 and	 2	µg/mL	
aprotinin).	Crude	lysates	were	centrifuged	for	5	min	at	14,000	rpm	to	remove	nuclei	and	
cell	debris.	The	supernatant	was	taken	and	protein	concentration	was	determined	using	
the	Lowry	method	(138).		
	
2.5	Isolation	of	primary	rat	hepatocytes		
Hepatocytes	 from	male	 Sprague-Dawley	 rats	 (200–300	 grams)	were	 kindly	 provided	 by	
Dr.	 Dong	 Fu	 (Faculty	 of	 Pharmacy).	 In	 brief,	 hepatocytes	 were	 isolated	 by	 collagenase	
perfusion	with	flow	rates	of	16–18	ml/min	and	cultured	at	a	density	of	2	×	105	on	10	mm2	
dishes	coated	with	rat	tail	collagen	(118).	Cells	were	 incubated	±	0.6	mM	OA	overnight,	
lysed	and	analyzed	by	western	blotting	(see	2.8).	
	
2.6	Preparation	of	mouse	liver	tissue	samples	
Mouse	 liver	 tissue	 samples	 from	wildtype,	ob/ob,	db/db,	db/+	animals	 as	well	 as	 livers	
from	 animals	 after	 4	 or	 40	 weeks	 of	 Chow	 or	 high	 fat	 diet	 (HFD)	 feeding	 were	 kindly	
provided	 by	 A/Prof.	 Nigel	 Turner,	 UNSW	 (Sydney,	 Australia).	 The	 liver	 samples	 were	
stored	at	-80°C.		
																																		 	
Figure	8:	Mouse	liver	tissue	samples	before	and	after	homogenization		
	
For	protein	extraction,	tissue	samples	were	placed	in	an	Eppendorf	tube	and	thawed	on	
ice.	500-1000	µL	of	ice	cold	lysis	buffer	(with	additives	as	above,	see	2.3)	was	added	and	
samples	were	incubated	on	a	roller	at	4	°C	for	30	min.	The	sample	was	then	homogenized	
(see	 Fig.	 8)	 using	 the	 PolytronÒ	 ball	 bearing	 homogeniser	 (Kinematica,	 Luzern,	
Switzerland).	 The	 sample	 was	 then	 centrifuged	 at	 13,000	 rpm,	 4	 °C	 for	 20	 min.	 The	
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supernant	was	 collected	 and	 protein	 content	was	 determined	 using	 the	 Lowry	method	
(138).	 Equal	 amounts	 of	 protein	 were	 then	 analyzed	 by	 western	 blotting	 as	 described	
below	(see	2.8).	
	
2.7	Subcellular	fractionation	
2.7.1	HuH7	LD	preparation	
An	enriched	LD	fraction	was	obtained	by	density	gradient	centrifugation,	using	a	protocol	
adapted	 from	 Brasaemle	 and	 Wolins	 (25).	 	 For	 each	 condition,	 8	 x	 10	 cm2	 dishes	 of	
confluent	HuH7-WT	and	HuH7-A6	cells	were	incubated	overnight	±	0.6	mM	OA,	washed	
and	scraped	with	ice-cold	PBS,	and	pelleted	by	centrifugation	for	10	min	at	1,000	g	at	4	
°C.	The	cell	pellet	was	 resuspended	 in	hypotonic	 lysis	buffer	 (HLM;	20	mM	Tris-HCl,	pH	
7.4,	 1mM	 EDTA,	 10	 mM	 NaF,	 0.5	 %	 (v/v)	 2-mercaptoethanol,	 0.1	 mM	 Na3VO4,	 1	 mM	
phenylmethulsolfonyl	 fluoride	 (PMSF),	 5	 µg/mL	 leupeptin	 and	 2	 µg/mL	 aprotinin)	 and	
samples	 were	 kept	 on	 ice	 for	 10	min	 prior	 to	 homogenization	 with	 6-8	 gentle	 strokes	
using	a	tissue	grinder	with	Teflon	pestle.	The	homogenate	was	centrifuged	for	10	min	at	
1,000	g	at	4	°C	and	the	supernatant	was	taken.	This	was	adjusted	to	a	final	concentration	
of	20	%	sucrose	(in	HLM)	and	layered	onto	the	bottom	of	a	5	mL	ultracentrifuge	fitting	the	
SW	55	Ti	rotor	(swinging	bucket,	Beckman	Coulter).	This	was	overlayed	with	an	equivalent	
volume	of	 5	%	 sucrose	 in	HLM,	 followed	 by	 a	 further	 layer	 of	HLM.	 The	 discontinuous	
gradient	was	 created	at	 4	 °C	 to	prevent	mixing	of	 the	 layers.	 The	 final	 volume	of	 each	
gradient	was	4.5	mL.	The	gradient	samples	were	centrifuged	for	30	min	at	28,000	g,	4	°C	
in	 the	 Beckman	 Coulter	 L-90K	 ultracentrifuge,	 with	 the	 slowest	 deceleration	 rate.	
Immediately	 following	 centrifugation,	 the	 samples	were	 fractionated,	 taking	9	 x	500	µL	
fractions	 from	top	 to	bottom.	The	 top	 two	 fractions	contained	 the	cloudy,	 lipid	droplet	
enriched	material	and	triglycerides	were	measured	as	described	below	(see	2.9).	
	
2.7.2	Rat	liver	LD	fractionation	
LDs	 were	 isolated	 in	 collaboration	 with	 Dr.	 Andrew	 Hoy	 (Charles	 Perkins	 Center,	
University	of	Sydney)	from	freshly	minced	rat	 livers	using	the	method	of	Brasaemle	and	
Wolins	(25).	Liver	was	minced	in	a	1:4	(w/v)	ratio	in	HML	buffer	(20	mM	Tris-HCl	pH	7.6,	1	
mM	EDTA,	10	mM	NaF	and	protease/phosphatase	inhibitor	cocktail	(Astral))	and	dounce	
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homogenized	 on	 ice.	 The	 lysate	 was	 centrifuged	 for	 10	 min	 at	 1,000	 g.	 The	 resulting	
supernatant	was	mixed	3:1	(v:v)	with	60	%	sucrose	(in	HML),	layered	with	5	%	sucrose	(in	
HLM),	 then	with	HLM	buffer.	 Samples	were	 centrifuged	 at	 28,000	 g	 for	 30	min	 at	 4	 °C	
using	 an	 SW41-Ti	 rotor	 (Beckman).	 	 The	 LD	 containing	band	was	 transferred	 to	 a	 fresh	
tube	and	the	protein	precipitated	in	10	volumes	of	acetone	overnight	at	-80°C.	Samples	
were	 mixed	 by	 inversion	 and	 centrifuged	 at	 4,300	 g	 for	 1	 h	 at	 4°C.	 The	 acetone	 was	
decanted	and	 residual	 solvent	 removed	 from	 the	protein	pellet	under	gentle	 stream	of	
nitrogen.	 LD	 proteins	 were	 resuspended	 in	 6	 M	 urea,	 2	 M	 thiourea,	 25	 mM	
triethylammonium	 bicarbonate	buffer,	 0.1	 %	 SDS,	 pH	 7.5,	 separated	 by	 SDS-PAGE	 and	
analysed	by	western	blotting	(see	2.8).	
	
2.8	SDS-PAGE	and	western	blotting	
Following	 protein	 quantification	 (138),	 equal	 amounts	 of	 protein	 (12-50	 µg)	 were	
denatured	by	addition	of	5x	Laemmli	Sample	buffer	(LSB).	Samples	in	LSB	were	boiled	for	
5	min,	then	cooled	on	ice	for	5	min,	then	centrifuged	for	a	further	5	min	at	13,000	rpm.	
12-50	µg	protein	was	 loaded	per	 lane	onto	SDS-PAGE	gels	 composed	of	 a	 resolving	gel	
containing	8-12	%	acrylamide	(Amresco,	Solon,	OH,	USA)	and	a	stacking	gel	containing	4	%	
acrylamide.	 Gels	 were	 run	 using	 a	 Bio-Rad	 Mini-Protean	 gel	 apparatus	 (Bio-Rad	
Laboratories,	Hercules,	CA,	USA)	with	running	buffer	(25	mM	Tris,	192	mM	glycine,	0.1%	
(w/v)	SDS)	at	200	V.	PageRulerÒ	prestained	protein	ladder	(Fermentas	by	Thermo	Fisher	
Scientific)	was	used	to	visualize	separation	of	proteins	and	to	determine	molecular	weight	
of	protein	bands.	Proteins	were	transferred	onto	poly-vinyl-D-fluoride	(PVDF)	membranes	
(0.2	µm	pore	size,	Merck	Milipore),	which	were	prepared	by	washing	the	membranes	in	
methanol	for	15	seconds,	deionised	H2O	for	1	min	and	then	transfer	buffer	(15	mM	Tris,	
120	mM	glycine,	20	%	(v/v)	methanol)	for	1	min.	Transfer	was	performed	in	the	Bio-Rad	
Mini-Protean	wet	transfer	system	(Bio-Rad	Laboratories)	for	2	h	at	70	V	or	17	h	at	20	V,	at	
4	°C.	Membranes	were	then	blocked	 in	5	%	(w/v)	skim	milk	powder	or	BSA	 in	PBS	with	
0.01	%	(v/V)	Tween-20	(PBS-T)	for	1	h	at	room	temperature.	Membranes	were	incubated	
in	primary	antibody	diluted	at	1:1000	in	1	%	(w/v)	skim	milk	or	BSA	in	PBS-T	overnight	at	4	
°C	on	a	roller	mixer.	Membranes	were	then	washed	three	times	in	PBS-T	and	incubated	
with	HRP-conjugated	secondary	antibody	(1:2000-1:5000)	in	1	%	(w/v)	skim	milk	or	BSA	at	
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room	 temperature.	 Subsequently,	 membranes	 were	 washed	 three	 times	 in	 PBS-T	 and	
proteins	 were	 visualized	 using	 Western	 LightingÒ	 Plus-ECL	 (enhanced	
chemiluminescence)	 substrates	 (Perkin	 Elmer,	 Waltham,	 MA,	 USA)	 according	 to	
manufacturer’s	 instructions.	 Membranes	 incubated	 in	 ECL	 were	 exposed	 to	 X-ray	 film	
(Fujifilm,	Tokyo,	Japan)	for	various	periods	of	time,	optimized	per	antibody.	Densitometry	
was	carried	out	using	ImageJ	1.47v	(National	Institutes	of	Health,	Betheseda,	MD,	USA).				
	
2.9	Triglyceride	quantification	from	LD	fractions	
Triglycerides	 in	LD	fractions	from	HuH7-WT	and	HuH7-A6	cells	were	extracted	based	on	
the	method	of	Folch	et	al.	(139)	and	quantified	using	an	enzymatic	colorimetric	method	
(GPO-PAP	reagent,	Roche	Diagnostics)	according	to	the	manufacturer’s	instructions.	
	
2.10	Statistical	analysis	
Data	 collection	 was	 carried	 out	 using	Microsoft	 Excel	 (Redmond,	WA,	 USA).	 Statistical	
analysis	was	 carried	out	 using	Graphpad	Prism	6	 (Graphpad,	 La	 Jolla,	 CA,	USA).	Graphs	
represent	 the	mean	 of	 2	 independent	 experiments	 unless	 stated	 otherwise,	 and	 error	
bars	show	the	standard	error	of	the	mean	(SEM).		
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3.	Results	
3.1	 AnxA6	 upregulation	 increases	 triglyceride	 accumulation	 in	 lipid	
droplets		
Recent	 findings	 from	 the	 Grewal	 group	 implicated	 that	 AnxA6	 expression	 levels	
modulated	the	ability	of	hepatocytes	to	store	triglycerides	in	lipid	droplets	(118).	In	fact,	
incubation	 of	 HuH7	 hepatocytes	 stably	 overexpressing	 AnxA6	 resulted	 in	 an	 increased	
accumulation	of	triglycerides,	as	judged	by	increased	neutral	lipid	staining	in	fluorescence	
microscopy	and	 flow	cytometry	studies,	 reflecting	 increased	LD	 formation	and	numbers	
(118).	 To	 further	 support	 these	 findings	 with	 biochemical	 approaches,	 we	 aimed	 to	
compare	 the	 triglyceride	 concentration	 of	 lipid	 droplets	 isolated	 from	wildtype	 (HuH7-
WT)	and	AnxA6	overexpressing	(HuH7-A6)	HuH7	hepatocytes	upon	incubation	with	oleic	
acid.		
	
Figure	 9:	 Increased	 triglyceride	 accumulation	 of	 AnxA6	 overexpressing	 HuH7	
hepatocytes.	2.5	x	108	wildtype	 (WT)	and	AnxA6	overexpressing	 (A6)	HuH7	hepatocytes	
were	 incubated	 with	 0.6	 mM	 OA	 overnight,	 lysed	 and	 fractionated	 on	 a	 discontinuous	
sucrose	gradient	as	described	(25).	The	 lipid	droplet	 fraction	at	the	top	of	each	gradient	
was	 isolated	 and	 the	 triglyceride	 concentration	 was	 determined	 as	 described	 (see	
Methods	 for	 further	 details).	 Triglyceride	 concentrations	 were	 obtained	 from	 single	
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samples	 per	 condition	 only.	 Western	 blot	 analysis	 for	 endogenous	 and	 overexpressed	
AnxA6	levels	in	the	cell	lines	are	shown;	b-actin	served	as	loading	control.	
	
Using	a	protocol	adapted	from	Brasaemle	and	Wolins	 (25),	subcellular	fraction	enriched	
with	lipid	droplets	from	HuH7-WT	and	-A6	cells	incubated	with	and	without	0.6	mM	oleic	
acid	was	obtained	by	density	gradient	centrifugation.	For	each	condition,	approximately	
2.5	x	107	cells	were	homogenized	and	separated	on	a	discontinuous	sucrose	gradient.	The	
top	two	fractions	of	each	gradient	contained	the	cloudy,	lipid	droplet	enriched	material,	
which	were	pooled	for	the	determination	of	the	triglyceride	concentration	(Fig.	9).	
	
In	 this	 experiment,	 triglyceride	 levels	 in	 LD	 from	 HuH7-WT	 and	 HuH7-A6	 cells	 under	
control	 conditions	 were	 comparable	 (approximately	 60-70	 nmol	 TG/LD	 fraction).	
However,	and	further	supporting	the	previous	findings	from	the	Grewal	group	(118),	TG	
levels	 raised	 to	 ~280	 nmol/LD	 in	 HuH7-WT,	 and	 to	 ~370	 nmol	 TG/LD	 in	 HuH7-A6	 cells	
upon	incubation	with	oleic	acid	overnight.	It	should	be	noted	that	due	to	time	constraints	
of	 this	 thesis,	 we	were	 unable	 to	 prepare	 and	 analyze	more	 than	 a	 single	 sample	 per	
condition.	 Nevertheless,	 despite	 the	 lack	 of	 statistical	 significance,	 these	 numbers	
indicate	 trends	 that	 are	 in	 line	 with	 increased	 neutral	 lipid	 staining	 observed	 in	
fluorescence	microcopy	studies	of	OA-loaded	HuH7-A6	cells	(118).	Hence,	upregulation	of	
AnxA6	in	HuH7	hepatocytes	is	accompanied	by	an	increased	storage	of	triglycerides	in	LD.	
	
3.2	AnxA6	is	associated	with	lipid	droplets	in	hepatic	cells	
Although	 AnxA6	 is	 mainly	 localized	 at	 the	 plasma	 membrane	 and	 endosomal	
compartments,	 other	 cellular	 locations	 that	 contain	 AnxA6	 have	 also	 been	 described.	
Previous	 proteomic	 profiling	 from	 Grewal	 and	 coworkers	 and	 others,	 also	 identified	
AnxA6	 in	 LD	membrane	 preparations	 from	 rat	 liver	 hepatocytes	 and	mouse	 adipocytes	
(140,	 141).	 In	 addition,	 AnxA6	 co-localized	 with	 LD	 markers	 in	 differentiated	 3T3-L1	
adipocytes	 (117)	and	more	recently,	 in	HuH7	hepatocytes	 (118).	To	 further	validate	 the	
association	of	AnxA6	with	LD,	we	next	aimed	to	demonstrate	 the	presence	of	AnxA6	 in	
purified	LD	isolated	from	rat	livers,	a	model	relevant	for	other	rodents	and	humans,	and	
commonly	used	to	investigate	LD	biology	(117,	128,	139,	142).	
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Therefore	lysates	from	freshly	minced	rat	livers	were	prepared	and	cellular	fractions	were	
separated	on	a	discontinuous	sucrose	gradient	described	by	Brasaemle	and	Wolins	(25).	
The	 LD	 containing	 band	 at	 the	 top	 of	 the	 gradient	 was	 isolated,	 and	 LD-associated	
proteins	 were	 precipitated	 with	 acetone	 at	 -80°C.	 LD	 proteins	 were	 resuspended,	 and	
together	 with	 aliquots	 from	 the	 whole	 cell	 lysates,	 separated	 by	 SDS-PAGE	 and	 then	
analysed	 by	 western	 blotting	 (Fig.	 10).	 As	 subcellular	 fractionations	 often	 suffer	 from	
contamination	 with	 other	 cellular	 organelles,	 we	 examined	 the	 LD	 enrichment	 of	 this	
fraction	 with	 antibodies	 enriched	 in	 other	 organelles.	 Therefore,	 we	 screened	 for	 the	
presence	 of	 Erp72,	 a	 well-established	 ER	 marker	 protein.	 Adipose	 triglyceride	 lipase	
(ATGL)	served	as	a	marker	for	LD	(129,	143)	In	addition,	we	compared	the	expression	of	
mitochondrial	 (cytochrome	 C;	 CytC),	 plasma	 membrane	 (NaK-ATPase)	 and	 endosomal	
proteins	(Rab11)	(88).		
	
Figure	10.	AnxA6	is	associated	with	LD	in	rat	liver.	Lipid	droplets	(LD)	were	isolated	from	
rat	 livers	 and	 LD	 proteins	were	 extracted	 as	 described	 (see	Methods	 for	 details).	Crude	
extracts	 (CE)	 and	 LD	 fractions	 were	 analyzed	 by	 western	 blotting	 for	 the	 presence	 of	
annexin	A6	 (AnxA6),	 adipose	 triglyceride	 lipase	 (ATGL),	and	markers	 for	 the	 ER	 (Erp72),	
mitochondria	 (cytochrome	 C,	 Cyt	 C),	 plasma	membrane	 (Na/K-ATPase)	 and	 endosomes	
(Rab11)	as	indicated.	
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Western	blot	 analysis	 confirmed	 the	enrichment	of	 the	 LD	 fraction	with	 the	 LD	marker	
ATGL	(Fig.	10).	In	addition,	the	ER-resident	protein	Erp72	is	also	found	in	the	LD	fraction,	
highlighting	that	LD	orginate	from	the	ER.	These	findings	underline	an	ongoing	limitation	
in	the	field,	as	LDs	 isolated	from	liver	tissue	generally	also	contain	ER-resident	proteins,	
making	 it	 difficult	 to	 clearly	 separate	 the	 LD	 from	 the	 ER	 proteome.	 In	 contrast,	
mitochondrial,	plasma	membrane	as	well	as	endosomal	marker	proteins	detectable	in	the	
whole	 cell	 lysate	were	 absent	 in	 the	 LD	 fraction,	 pointing	 at	 the	 LD	 enrichment	 of	 this	
fraction.	Moreover,	significant	amounts	of	AnxA6	were	associated	with	LD	from	rat	liver.	
Given	that	AnxA6	has	up	to	date	not	been	identified	in	the	ER	(93,	116,	144),	and	together	
with	the	co-localization	studies	of	the	Grewal	group	with	LD	marker	proteins	(118),	these	
findings	strongly	suggest	association	of	AnxA6	with	LD	in	hepatic	tissue.	
	
3.3	Effect	of	various	lipid-altering	conditions	of	AnxA6	and	c-PLA2	levels	in	
hepatocytes		
In	 light	 of	 previous	 findings	 from	 the	 Grewal	 group	 and	 others,	 AnxA6	 has	 a	 known	
association	 with	 lipid	 metabolism	 (64,	 67,	 84,	 116).	 The	 majority	 of	 data	 implicating	
AnxA6	in	cholesterol	and	FA	metabolism	have	been	derived	from	gain-	or	loss-of	function	
models	 in	cell	culture	and	mouse	models	 (116,	118).	Likewise,	recent	studies	examining	
AnxA6	function	 in	LD	formation	utilized	AnxA6	overexpression	and	knockdown	cell	 lines	
(118).	 To	 put	 this	 into	 a	more	 physiological	 context,	we	 therefore	 aimed	 to	 examine	 if	
AnxA6	 levels	would	be	up-	or	 -downregulated	upon	environmental	changes	that	 impact	
on	hepatic	lipid	metabolism.		
	
The	 protein	 expression	 of	 AnxA6	 was	 analysed	 in	 response	 to	 various	 lipid-altering	
conditions,	 mimicking	 lipid-altering	 conditions	 experienced	 in	 health	 and	 disease.	 The	
human	HuH7	 hepatocarcinoma	 cell	 line	 served	 as	 our	model	 as	 this	 cell	 line	 has	 been	
commonly	used	to	examine	hepatic	lipid	metabolism	and	lipid	droplet	biology	(118).	
	
The	cells	were	cultured,	starved	for	24	h	and	treated	for	48	h	with	OA	(0.6	mM),	0.1	%	
FCS,	a	PPARa	 agonist	 (Wy-14643),	or	analysed	after	 lipid	 starvation	 (10	%	LPDS)	or	 LDL	
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loading	(50	µg/ml).	OA	is	a	monounsaturated	fatty	acid	that	is	commonly	used	to	induce	
TG	accumulation,	 LD	 formation	mimicking	hepatosteatosis	 (145,	146).	Both	OA	and	 the	
saturated	 fatty	 acid	 palmitic	 acid	 (PA),	 are	 the	 most	 prominently	 featured	 fatty	 acids	
contributing	 to	Western	 diets	 implicated	 in	 disease	 states	 such	 as	 NAFLD	 and	 obesity	
(145).	 	In	vitro	studies	reveal	OA	supplementation	is	preferred	over	PA	in	the	context	of	
modeling	steatogenesis	in	hepatocytes,	as	it	 is	more	steatogenic	but	less	apoptotic	than	
palmitic	acid	in	hepatocytic	cell	cultures	(146).		
	
Therefore	 cells	were	 treated	with	OA	at	 a	 concentration	of	 0.6	mM	OA	 for	24-48	h,	 to	
induce	cellular	TG	accumulation	and	lipid	droplet	formation	(34).		
	
Figure	11.	AnxA6	expression	 in	response	to	various	 lipid-modifying	conditions.	Huh7wt	
cells	were	starved	for	24	h,	treated	with	oleic	acid	(0.6	mM),	0.1	%	FCS,	Wy	(20	µM),	10	%	
LPDS	or	10	%	LPDS	with	LDL	(50	µg/mL)	for	48h,	prior	to	cell	lysis,	SDS-PAGE	and	western	
blot	analysis.	AnxA6	expression	was	quantified	and	normalized	to	b-actin	using	ImageJ	of	
AnxA6	and	actin	levels	(Mean	+/-	SEM,	n=2).	
	
The	effects	of	starvation	on	expression	levels	was	assessed	by	treatment	with	0.1	%	FCS.	
Under	 these	 conditions,	 hepatic	 cells	 induce	 cholesterol	 and	 fatty	 acid	 synthesis	 (22).	
Further,	to	examine	the	effects	of	a	potent	TG-lowering	agent	that	induces	b-oxidation	in	
hepatocytes,	 cells	 were	 treated	with	Wy-14643	 (147,	 148).	 Treatment	with	 lipoprotein	
deficient	 serum	 (LPDS),	 modeled	 a	 setting	 devoid	 of	 cholesterol	 or	 triglyceride-rich	
lipoproteins.	 Cholesterol	 from	 LDL	 as	 well	 as	 triglycerides	 from	 chylomicrons	 can	
accumulate	 in	 LD	 of	 hepatic	 cells,	 contributing	 to	 lipid	 accumulation	 in	 liver	 disease.	
Hence,	as	the	Grewal	group	had	previously	identified	that	AnxA6	upregulation	increased	
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LDL	 endocytosis,	 but	 interfered	 with	 LDL-cholesterol	 distribution	 inside	 cells	 (81,	 82),	
incubations	with	LPDS	with	and	without	LDL	loading	were	analysed.	
	
Following	treatment,	cells	were	lysed	and	crude	cell	lysates	were	prepared.	Equal	amount	
of	 protein	 was	 separated	 on	 12%	 SDS-PAGE	 and	 then	 analysed	 by	 WB	 for	 AnxA6	
expression	levels	(Fig.	11).		AnxA6	levels	were	observed	in	control	HuH7-WT	cells,	which	is	
consistent	 with	 previous	 results	 from	 Grewal	 and	 coworkers	 (118).	 For	 all	 other	
conditions,	 we	 observed	 a	 2-2.5	 fold	 increase	 in	 AnxA6	 expression.	 Despite	 the	 large	
deviation	 in	between	 independent	experiments,	 these	 findings	 indicate	 that	 changes	 in	
the	lipid	status	of	cells	may	be	associated	with	increased	AnxA6	protein	levels.	
	
3.4	 AnxA6	 protein	 expression	 in	 other	 hepatic	 cell	 lines	 and	 primary	 rat	
hepatocytes	
Findings	 described	 above	 (Fig.	 11)	 suggested	 that	 increased	 TG	 accumulation	 caused	
AnxA6	upregulation	 in	HuH7	hepatocytes.	To	confirm	these	 findings,	we	next	examined	
other	hepatocyte	models.	Given	that	primary	hepatocytes	are	considered	the	cell	model	
of	 reference	 for	studies	 related	to	 liver	 function,	we	next	analyzed	AnxA6	expression	 in	
primary	rat	hepatocytes.	
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Figure	 12:	 AnxA6	 expression	 in	 (A)	 primary	 rat	 hepatocytes	 and	 (B)	 AML12	 mouse	
hepatocytes	 in	the	presence	or	absence	of	OA.	Primary	rat	hepatocytes	 (A)	and	AML12	
(B)	were	treated	±	OA	(0.6	mM)	as	indicated.	Recovery	indicates	removal	of	OA	after	24	h	
loading,	followed	by	additional	48	h	incubation.	Cells	were	lysed	and	analysed	by	western	
blotting.	TG	levels	to	verify	OA	accumulation	and	OA	reduction	after	removal	(‘Recovery’)	
is	shown	(n=6	per	condition).	The	blots	are	representative	for	2	independent	experiments	
with	triplicate	(A)	or	duplicate	(B)	samples.	
	
Therefore,	hepatocytes	from	male	Sprague-Dawley	rats	(200–300	grams)	were	isolated	by	
collagenase	perfusion	and	cultured	on	10	mm	dishes	coated	with	 rat-tail	 collagen.	24	h	
after	 plating,	 cells	 were	 incubated	 with	 0.6	 mM	 OA	 overnight,	 lysed	 and	 analyzed	 by	
western	 blotting	 (Fig.	 12)	 (149).	 In	 contrast	 to	 the	 findings	 obtained	 from	 OA-loaded	
HuH7	hepatocytes,	AnxA6	levels	remained	unchanged	in	rat	hepatocytes	in	the	presence	
or	absence	of	OA.	
	
We	next	examined	AML12,	a	mouse	hepatocyte	cell	line	used	by	many	researchers	(10).	
In	line	with	the	data	obtained	from	primary	rat	hepatocytes	we	were	unable	to	observe	
significant	alterations	 in	AnxA6	protein	 levels	upon	OA	loading	(Fig.	12).	 Interestingly,	 in	
this	 cell	 line,	 AnxA6	 levels	 were	 upregulated	 upon	 removal	 of	 OA	 and	 further	 48	 h	
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incubation	in	the	absence	of	OA.	Similarly,	AnxA6	protein	 levels	remained	unchanged	in	
the	 commonly	 used	 HepG2	 cell	 line	 in	 the	 presence	 or	 absence	 of	 OA	 (118).	 Taken	
together,	AnxA6	protein	levels	appear	upregulated	in	some,	but	not	all	hepatic	cell	lines,	
upon	OA	loading.	
	
3.5	 AnxA6	 mRNA	 expression	 is	 not	 elevated	 upo	 OA	 loading	 in	 HuH7	
hepatocytes		
Western	blot	analysis	in	HuH7	hepatocytes	indicated	that	OA	loading	led	to	an	increase	in	
endogenous	AnxA6	protein	levels	(Fig.	12).	These	findings	supported	similar	results	from	
Grewal	and	coworkers	(118).	However,	other	hepatic	cell	lines	of	human	or	mouse	origin	
including	HepG2	 (118),	AML12	 (Fig.	12B),	or	primary	 rat	hepatocytes	 (Fig.	12A),	did	not	
reveal	 alterations	 in	 AnxA6	 protein	 levels	 upon	 OA	 loading.	 Hence,	 these	 findings	
indicated	 that	 in	 some,	 but	 not	 all	 hepatic	 cell	 lines,	 triglyceride	 accumulation	 could	
regulate	 AnxA6	 expression	 at	 the	 transcriptional	 or	 post-transcriptional	 level.	 To	
investigate	 this	 further,	 we	 next	 aimed	 to	 determine	 if	 AnxA6	 mRNA	 levels	 would	 be	
affected	by	OA	loading.		
	
Therefore	 the	 human	 hepatic	 cell	 lines	 HuH7	 and	 HepG2	 were	 incubated	 with	 and	
without	0.6	mM	OA	as	described.	Following	treatments,	cells	were	lysed,	total	RNA	was	
isolated	 and	 cDNA	was	 synthesized	with	 random	hexamer	 primers	 (see	 Section	 2.3	 for	
details).	Relative	mRNA	levels	for	AnxA6,	AnxA2	and	the	housekeeper	control	(28s	RNA)	
were	 then	 determined	 by	 quantitative	 real-time	 PCR	 in	 triplicates	 using	 SYBR-Green	 in	
collaboration	 with	 Prof.	 Katia	 Monastrykaya	 as	 described	 previously	 (150).	 The	 end	
products	 of	 all	 PCR	 reactions	were	 analyzed	 on	 4	%	 low	melting	 point	 agarose	 gels	 to	
validate	 the	 correct	 fragment	 size.	 The	 relative	 expression	 of	 AnxA2	 and	 AnxA6	 was	
calculated	 by	 correlating	 the	 normalised	 Ct	 values	 of	 OA-incubated	 samples	 to	 the	
untreated	controls	(ΔΔCt	method).			
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Figure	13:	AnxA6	mRNA	expression	 in	HuH7	and	HepG2	heptocyte	cell	 lines.	HuH7-WT	
and	HepG2	were	treated	±	0.6	mM	OA	for	24	h.	RNA	was	isolated	and	analysed	by	RT-PCR	
for	 the	 expression	 of	 AnxA2	 and	AnxA6.	 The	 relative	mRNA	 levels	 of	 AnxA2	 and	AnxA6	
normalized	to	the	housekeeper	gene	28s	rRNA	are	given	and	presented	as	-fold	difference	
compared	to	untreated	control.	The	data	represents	the	mean	±	SD	from	two	independent	
experiments	with	triplicate	samples.		
	
In	these	set	of	experiments,	AnxA6	as	well	as	AnxA2	mRNA	expression	was	comparable	in	
HuH7-WT	 and	 HepG2	 in	 the	 presence	 or	 absence	 of	 OA	 (Fig.	 13).	 AnxA6	 (and	 AnxA2)	
mRNA	levels	also	remained	relatively	constant	in	HuH7	and	HepG2	cells	incubated	with	1	
%	 FCS,	 LPDS,	 fenofibrate,	 liver	 X	 receptor	 agonists	 (LXR)	 and	 statins,	while	 other	 genes	
known	to	be	upregulated	by	cholesterol	depletion	or	LXR	agonists	(LDL	receptor,	PCSK9)	
confirmed	that	the	methodology	was	appropriate	to	detect	change	 in	mRNA	expression	
levels	 (data	 not	 shown).	 Hence,	 increased	 AnxA6	 protein	 stability	 rather	 than	
transcriptional	 regulation	 may	 explain	 upregulated	 AnxA6	 protein	 levels	 in	 OA-loaded	
HuH7	hepatocytes.	Nevertheless,	and	as	discussed	 in	more	detail	 in	 the	discussion	 (see	
Chapter	4.3	for	details),	despite	the	differential	behaviour	of	AnxA6	protein	levels	in	the	
various	hepatic	cell	models	(Fig.	11-12),	several	studies	in	humans,	mouse	models	and	cell	
culture	suggest	metabolic	stress	conditions	to	impact	on	hepatic	AnxA6	expression.		
	
3.6	Analysis	of	AnxA6	expression	 in	OA-loaded	HuH7	cells	overexpressing	
or	lacking	AnxA6		
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The	findings	described	above	 indicated	post-transcriptional	upregulation	of	endogenous	
AnxA6	in	OA-loaded	HuH7-WT	cells	(Fig.	11-13).			
	
Figure	 14.	 AnxA6	 expression	 in	 Huh7-WT	 (WT),	 HuH7	 stably	 overexpressing	 AnxA6	
(AnxA6-OE),	 or	 with	 stable	 AnxA6	 knockdown	 (AnxA6-KD)	 in	 response	 to	 fatty	 acid	
accumulation.	Cells	were	treated	±	0.6	mM	OA	for	24h	±	recovery	for	48	h	(OA+Recovery).	
Cells	 were	 lysed,	 separated	 on	 10	 %	 SDS-PAGE	 and	 AnxA6	 and	 b-actin	 levels	 were	
determined	by	western	blotting.	AnxA6	and	actin	in	Huh7-WT	and	Huh7-AnxA6	(A),	HuH7-
WT	and	HuH7-AnxA6-KD	(B)	and	the	quantification	of	AnxA6	levels	normalized	to	b-actin	
is	shown	in	(C).	Mean	±	SEM,	n=2.	
	
To	 assess	 if	 triglyceride	 accumulation	 would	 also	 impact	 on	 the	 protein	 levels	 of	
ectopically	 expressed	 AnxA6,	 we	 next	 analysed	 the	 HuH7	 cell	 line	 stably	 expressing	
AnxA6.	Cells	were	treated	±	0.6	mM	OA	for	24	h	±	recovery	for	48	h	(OA+Recovery).	Cell	
lysates	were	prepared	and	AnxA6	and	b-actin	levels	were	determined	by	western	blotting	
(Fig.14A,	for	quantification	see	14C).	Despite	b-actin	blots	revealing	apparent	differences	
in	the	amount	of	protein	that	was	analysed,	the	quantification	of	these	blots	nevertheless	
provided	 trends	 that	were	 similar	 to	 other	 independent	 experiments	 performed	 in	 the	
Grewal	laboratory	(118).	In	support	of	the	previous	findings	(Fig.	11)	and	published	data	
(118),	AnxA6	protein	levels	in	HuH7-WT	cells	were	slightly	increased	upon	OA	loading	and	
remained	 elevated	 after	 OA	 removal	 for	 additional	 48	 h	 (OA	 +	 Recovery).	 Expression	
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levels	of	ectopically	expressed	AnxA6	remained	constant	±	OA	loading,	yet	were	slightly	
elevated	during	Recovery.		
	
We	then	analysed	the	impact	of	triglyceride	accumulation	on	AnxA6	expression	levels	in	
the	 HuH7	 cell	 line	 with	 stable	 AnxA6	 knockdown.	 This	 AnxA6-specific	 knockdown	 was	
generated	 using	 a	 commercial	 shRNA	 vector	 targeting	 human	 AnxA6	 and	 resulted	 in	
approximately	80%	depletion	of	AnxA6	protein	levels	(Fig.	14B-C)	(87,	143),	OA	loading	as	
well	as	recovery	did	not	significantly	impact	on	the	stability	of	the	residual	AnxA6	protein	
levels	observed	in	this	cell	line.	Taken	together,	while	OA	loading	increased	AnxA6	protein	
levels,	 most	 likely	 via	 post-transcriptional	 pathways,	 this	 regulatory	 pathway	 did	 not	
significantly	impact	on	ectopically	expressed	AnxA6	in	HuH7-A6,	nor	did	it	interfere	with	
AnxA6	knockdown	in	HuH7-A6KD.		
	
3.7	Analysis	of	AnxA6	expression	in	mouse	models	of	insulin	resistance	and	
diabetes	
In	recent	years,	the	Grewal	group	and	collaborators	have	examined	AnxA6	expression	in	
various	 settings	 linked	 to	 obesity,	 insulin	 resistance,	 fatty	 liver	 and	 the	 metabolic	
syndrome.	 While	 AnxA6	 protein	 levels	 increased	 in	 white	 adipose	 tissues	 of	 obese	
mice	(117),	AnxA6	levels	in	the	fatty	liver	of	ob/ob	and	db/db	animals	and	in	human	fatty	
liver	 appeared	 comparable	 to	 controls	 (151).	Similarly,	AnxA6	 levels	were	unaffected	 in	
murine	nonalcoholic	steatohepatitis	and	human	liver	fibrosis	(151).		 
	
The	ob/ob	mouse	lacks	 production	 of	 leptin,	 which	 leads	 to	 excessive	 food	 intake	 and	
consequently,	 severe	 obesity.	It	 serves	 as	 a	 model	 for	 type	 II	 diabetes,	 which	 is	 not	
particular	severe	and	not	completely	representative	of	human	type	2	diabetes	(152).	The	
db/db	 mouse	 model	 lacks	 the	 leptin	 receptor	 and	 animals	 become	 obese,	
hyperinsulinaemic	 and	 hyperglycaemic	 after	 2–4	 weeks	 (152).	 Findings	 described	 for	
AnxA6	 expression	 levels	 described	 above	 were	 obtained	 from	 a	 limited	 number	 of	
animals	 (117,	151),	 and	given	 the	 large	variation	often	observed	when	comparing	gene	
and	 protein	 expression	 data	 from	 individual	 animals,	 we	 next	 compared	 AnxA6	
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expression	 in	 liver	 tissues	 from	ob/ob,	db/db	and	db/+	mice	 (kindly	provided	by	A/Prof.	
Nigel	Turner,	UNSW).		
	
	
Figure	15.	AnxA6	expression	in	liver	tissue	from	wildtype	(WT),	ob/ob,	db/db	and	db/+	
animals.	 Tissue	 samples	 were	 separated	 on	 10	 %	 SDS-PAGE	 and	 AnxA6	 and	 GAPDH	
protein	levels	were	determined	by	western	blotting	and	quantified	using	Image	J	(C).	The	
numbers	indicate	different	mice	(4-6	animals	per	model).	AnxA6	levels	were	normalized	to	
GAPDH.	
	
Therefore	approximately	100	mg	of	liver	tissue	from	mice	(4-6	animals	per	model)	were	
crushed	in	liquid	nitrogen	and	resuspended	in	lysis	buffer.	After	30	min	at	4	°C,	cell	debris	
was	removed	by	centrifugation	and	equal	amounts	of	protein	from	the	crude	lysates	were	
then	 separated	 by	 10	%	 SDS-PAGE,	 followed	 by	western	 blot	 analysis	 using	AnxA6	 and	
GAPDH	antibodies.	Irrespective	of	the	mouse	model	and	genetic	defect	analysed,	AnxA6	
expression	levels	varied	significantly	in	individual	animals	(Fig.	15A-B).	This	could	partially	
be	 attributed	 to	 the	 commonly	 observed	 variation	 in	 intact	 protein	 recovered	 when	
preparing	 liver	tissue	samples,	but	also	the	 inherent	attribute	of	mice	displaying	a	 large	
range	 of	 expression	 levels	 for	 most	 genes.	 Expression	 of	 hepatic	 AnxA6	 was	 slightly	
elevated	 in	ob/ob	mice,	 and	 slightly	 reduced	 in	 the	db/db	model,	 yet	 these	differences	
were	not	statistically	significant.	These	findings	suggest	that	genetic	defects	in	genes	that	
critically	 contribute	 to	 obesity	 and	 type	 2	 diabetes	 do	 not	 trigger	 changes	 in	 AnxA6	
expression	 levels	 in	 the	 liver.	However,	 as	 discussed	below	 (see	 Section	4.3),	 triggering	
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additional	stress	or	disease	conditions	in	these	mouse	models	could	alter	hepatic	AnxA6	
levels.	
	
3.8	 Analysis	 of	 AnxA6	 expression	 in	 high-fat	 diet-induced	 hyperlipidemia	
and	obesity	
Besides	 examining	 AnxA6	 levels	 in	 genetic	 models	 for	 obesity,	 fatty	 liver	 and	 insulin	
resistance	 (see	3.6),	Grewal	and	coworkers	also	determined	AnxA6	 levels	 in	 the	 liver	of	
mice	fed	a	high-fat	diet	(HFD).	 In	these	set	of	experiments	mice	were	kept	on	a	HFD	or	
standard	 chow	diet	 for	 14	weeks.	 After	 this	 period,	 HFD	 is	 known	 to	 increase	 plasma	
lipid	levels,	overall	body	weight,	liver	mass	and	show	signs	of	insulin	resistance.	AnxA6	
expression	 levels	 in	 the	 liver	 from	 HFD	 mice	 were	 comparable	 to	 controls	 (151)	
indicating	 that	 early	 stages	 of	 hepatic	 lipid	 accumulation	 do	 not	 cause	 alterations	 in	
AnxA6	expression.	 
 
To	examine	this	further,	we	next	compared	AnxA6	expression	after	4	weeks	and	40	weeks	
HFD	and	Chow	feeding.	While	animals	on	a	4	week	HFD	show	elevated	plasma	lipid	levels	
and	body	weight	 gain,	 prolonged	HFD	 feeding	 (40	weeks)	 is	 associated	with	 a	 stronger	
phenotype,	including	fatty	liver,	hyperlipidemia	and	insulin	resistance	(143,	151,	152).	
 
	
Figure	16.	AnxA6	expression	 in	 liver	 tissue	 from	mice	 fed	a	4	week	 (A)	or	40	week	 (B)	
standard	Chow	and	high	fat	diet.	Tissue	samples	from	male	C57/Bl6	mice	on	a	standard	
Chow	(Chow,	C)	or	high	fat	diet	(HFD,	H)	for	4	(A)	or	40	weeks	(B)	were	prepared	and	were	
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separated	 on	 10	 %	 SDS-PAGE.	 AnxA6	 and	 GAPDH	 protein	 levels	 were	 determined	 by	
western	blotting	and	quantified	using	Image	J	(C-D).	The	numbers	indicate	different	mice	
(4-6	animals	per	group).	AnxA6	levels	were	normalized	to	GAPDH.	
	
Tissue	 samples	 from	animals	were	kindly	provided	by	A/Prof.	Nigel	Turner	 (UNSW)	and	
prepared	 as	 described	 above	 (see	 Section	 3.6).	Unlike	 the	 published	 data	 (151),	 AnxA6	
expression	 levels	were	slightly	elevated	by	approximately	60%	after	a	4	weeks	HFD	diet	
(A,	C).	 In	contrast,	AnxA6	expression	was	reduced	by	approximately	30%	after	40	weeks	
HFD	 feeding.	 Although	 these	 findings	 were	 not	 statistically	 significant,	 Grewal	 and	
coworkers	 also	 noticed	 strong	 AnxA6	 downregulation	 during	 liver	 dysfunction	 induced	
after	 partial	 hepatectomy	 (Grewal	 and	 Enrich,	 unpublished	 observation),	 when	
hepatocytes	 are	 charcaterized	 by	 enhanced	 lipid	 droplet	 formation	 and	 neutral	 lipid	
storage.	Nevertheless,	while	the	trends	in	AnxA6	up-	and	downregulation	observed	after	
short	 or	 prolonged	 HFD	 feeding	 are	 exciting,	 the	 large	 variation	 of	 AnxA6	 expression	
levels	in	both	the	control	and	HFD	group,	as	well	as	the	limited	number	of	animals	should	
be	taken	into	consideration	and	future	experiments	with	larger	cohorts	would	be	needed	
to	further	support	these	findings.		
	
3.9	 Modification	 of	 lipid	 metabolism	 alters	 cPLA2α	 activity	 in	 HuH7	
hepatocytes	
Numerous	 proteins,	 including	 PAT,	 protein	 kinases	 and	 lipid-modifying	 enzymes	
contribute	to	LD	formation	(30,	35,	44,	153).	In	addition	to	neutral	 lipid	accumulation	in	
the	 ER	 (30,	 35,	 44,	 153),	 the	 formation	 of	 lysophospholipids	 in	 the	 ER	 also	 seems	 to	
contribute	 to	 LD	 biogenesis.	 Hence,	 glycerophospholipid	 turnover	 to	 generate	 positive	
membrane	curvature	would	promote	LD	budding	from	the	ER	(39,	40,	44).	In	support	of	
this	hypothesis,	cPLA2α	can	remove	fatty	acids	 from	glycerophospholipids	and	has	been	
proposed	to	stimulate	LD	formation	(39,	40,	42,	43).		
	
In	previous	studies	Grewal	and	coworkers	identified	that	AnxA6	overexpression	caused	an	
accumulation	of	cellular	cholesterol	in	late	endosomes.	This	was	accompanied	by	reduced	
cholesterol	 levels	in	other	compartments,	 including	the	Golgi	apparatus	(127).	In	follow-
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up	 studies	 the	Grewal	 group	 then	 demonstrated	 that	 reduced	 cholesterol	 levels	 in	 the	
Golgi	interfered	with	the	recruitment	of	cPLA2α	to	promote	cholesterol-sensitive	budding	
events	 of	 the	 secretory	 pathway	 emanating	 from	 the	 Golgi	 apparatus	 (84).	 Taken	
together,	 elevated	 AnxA6	 levels	 indirectly	 interfered	 with	 the	 cellular	 distribution	 and	
activity	of	cPLA2α.		
	
Given	that	AnxA6	expression	 levels	regulate	cPLA2α	 localization	and	activity	 in	the	Golgi	
apparatus,	we	next	aimed	to	identify	a	link	between	AnxA6	and	cPLA2α	in	the	context	of	
LD	 formation.	 The	 regulation	 of	 cPLA2α	 activity	 is	 complex,	 but	 phosphorylation	 at	 the	
Ser505	 residue	 is	 considered	 to	be	 representative	 for	 cPLA2α	 activation	 (40).	 Therefore	
we	 first	 examined	 if	 cPLA2α	 levels	 or	 activity	 would	 be	 up-	 or	 -downregulated	 upon	
environmental	changes	that	impact	on	hepatic	lipid	metabolism.	Therefore	and	alike	the	
experiments	 shown	 in	 section	 3.3	 (Fig.	 11),	 cells	were	 incubated	 ±	OA,	 0.1	%	 FCS,	Wy-
14643,	10	%	LPDS	±	LDL.	Following	treatment,	cells	were	lysed	and	crude	cell	lysates	were	
separated	 on	 12	 %	 SDS-PAGE	 and	 then	 analysed	 by	WB	 for	 phosphorylated	 and	 total	
cPLA2α	expression	levels.	
	
	
Figure	 17.	 cPLA2α	 expression	 and	 activity	 	 in	 response	 to	 various	 lipid-modifying	
conditions.	HuH7-WT	cells	were	starved	for	24	h,	treated	with	0.6	mM	OA,	0.1	%	FCS,	20	
µm,	 Wy-14643,	 10	 %	 LPDS	 ±	 50	 µg/ml	 LDL	 as	 indicated	 for	 48	 h.	 Cell	 lysates	 were	
prepared,	 separated	 by	 12	 %	 SDS-PAGE	 and	 analysed	 by	 western	 blotting	 for	
phosphorylated	 and	 total	 cPLA2α.	 The	 ratio	 of	 phosphorylated/total	 cPLA2α	 was	
quantified	using	ImageJ	(Mean	±	SEM,	n=2).	
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Significant	amounts	of	phosphorylated	and	total	cPLA2α	were	detectable	in	control	HuH7	
hepatocytes.	 Interestingly,	 incubation	 with	 OA,	 and	 starvation	 both	 increased	 cPLA2α	
activity	approximately	1.5	–	2.1-fold.	In	contrast,	treatment	with	the	PPARα	agonist	WY-
14643,	as	well	as	lipid	starvation,	strongly	reduced	cPLA2α	activity,	as	judged	by	a	strongly	
reduced	 cPLA2α	 Ser505	 phosphorylation.	 LDL	 loading	 partially	 restored	 cPLA2α	 activity.	
Some	of	these	findings	could	reflect	changes	 in	neutral	 lipid	storage	and	metabolism	as	
the	delivery	of	 large	amounts	of	 fatty	acids	 in	OA-incubated	cells	 requires	 increased	LD	
formation.	Likewise,	starvation	induces	fatty	acid	and	triglyceride	synthesis,	which	would	
be	 stored	 in	 LD.	 It	 is	 unknown	 if	 this	 process,	 which	 would	 implicate	 increased	 LD	
formation,	 is	 coupled	 to	 cPLA2	 activation.	 On	 the	 other	 hand,	 incubation	 with	 PPARα	
agonists	 would	 promote	 fatty	 acid	 oxidation,	 leading	 to	 reduced	 LD	 numbers	 (154).	
However,	if	PPARα	activation	alters	cPLA2	activity	is	yet	unknown.	LPDS	initially	depletes	
cells	 of	 cholesterol	 and	 other	 lipids,	 while	 LDL	 loading	 would	 increase	 the	 delivery	 of	
cholesteryl	esters	that	will	ultimately	be	stored	 in	LD.	Taken	together,	alterations	 in	the	
lipid	status	that	are	potentially	linked	to	neutral	lipid	storage	are	associated	with	changes	
in	cPLA2α	Ser505	phosphorylation.	
	
3.10	AnxA6	up-	or	downregulation	is	associated	with	changes	in	cPLA2α	
Ser505	phosphorylation	
Given	that	 triglyceride	accumulation	 increased	cPLA2α	Ser505	phosphorylation	 in	HuH7-
WT	hepatocytes	(Fig.	17),	we	next	examined	if	AnxA6	up-	or	downregulation	in	OA-loaded	
HuH7	 hepatocytes	 could	 impact	 on	 cPLA2α	 activity.	 Therefore	 HuH7-WT,	 HuH7-A6	 and	
HuH7-A6KD	 cells	were	 treated	 ±	 0.6	mM	OA	 for	 24	 h	 followed	 by	 ±	 recovery	 for	 48	 h	
(OA+Rec).	 Cell	 lysates	were	prepared	 and	phosphorylated	 and	 total	 cPLA2α	 levels	were	
determined	 by	western	 blotting	 (Fig.	 18).	 Despite	 total	 cPLA2α	 blots	 revealing	 reduced	
protein	amounts	being	analysed	 in	some	samples,	 the	quantification	of	these	blots	 (Fig.	
18B	 and	 D)	 nevertheless	 provided	 trends	 that	 were	 associated	 with	 AnxA6	 up-	 and	
downregulation.	 In	 support	 of	 the	 previous	 findings	 (Fig.	 17),	 cPLA2α	 Ser505	
phosphorylation	was	increased	upon	OA	loading	in	HuH7-WT	hepatocytes	(Fig.	18A-B).	In	
contrast	 cPLA2α	 Ser505	 phosphorylation	was	 reduced	 in	 the	HuH7-A6	 cell	 line,	 and	OA	
loading	did	not	increase	cPLA2α	Ser505	activity	(Fig.	18A-B).	Vice	versa,	AnxA6	depletion	
 
 
48 
in	 the	 HuH7-A6KD	 cell	 line	 was	 associated	 with	 strongly	 increased	 cPLA2α	 Ser505	
phosphorylation	in	control	and	OA-loaded	conditions	(Fig.	18C-D).		
	
Taken	 together,	 alterations	 in	 AnxA6	 expression	 levels	 in	 HuH7	 hepatocytes	 are	
associated	with	altered	cPLA2α	Ser505	phosphorylation	patterns.	 Somewhat	perplexing,	
elevated	AnxA6	levels	lead	to	increased	LD	formation	and	triglyceride	accumulation	(Fig.	
9;	 (118)),	 while	 AnxA6	 depletion	 is	 associated	 with	 reduced	 LD	 formation.	 Hence,	
reduced/elevated	 cPLA2α	 Ser505	 phosphorylation	 observed	 in	 HuH7-A6	 and	 HuH7-KD	
cells	does	not	seem	to	correlate	with	the	ability	of	these	cells	to	store	neutral	lipids	in	LD.		
	
The	molecular	mechanisms	that	may	enable	AnxA6	to	modulate	FA-induced	LD	formation	
in	hepatic	cells	remain	to	be	clarified.	This	likely	includes	cPLA2α-dependent	pathways,	as	
triglyceride	accumulation	was	insensitive	towards	pharmaceutical	inhibition	of	cPLA2α	in	
AnxA6-depleted	 HuH7	 hepatocytes	 (118).	 Yet,	 despite	 the	 mitogen–activated	 kinase	
Erk1/2	 phosphorylating	 cPLA2α	 at	 serine	 residue	 505,	 this	 activity	 is	 not	 required	 for	
cPLA2α-dependent	LD	formation	(39,	42,	43)	and	as	discussed	in	more	detail	below,	other	
criteria	in	relation	to	AnxA6,	such	as	the	regulation	of	cPLA2α	localization,	might	be	more	
relevant	for	LD	formation.		
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Figure	18.	Relative	cPLA2α	activity	in	Huh7-WT	(WT),	HuH7	stably	overexpressing	AnxA6	
(AnxA6-OE),	 or	 with	 stable	 AnxA6	 knockdown	 (AnxA6-KD)	 in	 response	 to	 fatty	 acid	
accumulation.	Cells	were	 treated	±	0.6	mM	oleic	acid	 (OA)	 for	24	h	±	 recovery	 for	48	h	
(OA+Rec).	Cells	were	lysed,	separated	on	10	%	SDS-PAGE	and	phosphorylated/total	cPLA2α	
expression	 levels	 were	 determined	 by	 western	 blotting.	 The	 relative	 cPLA2α	 activity	 (P-
cPLA2α/total	 cPLA2α)	 in	 HuH7-WT	 and	HuH7-AnxA6	 (A),	 HuH7-WT	 and	HuH7-AnxA6-KD	
(B)	is	shown.	Mean	±	SEM,	n=2.	
	
3.11	 Pharmacological	 inhibition	 of	 cPLA2α	 in	 OA-loaded	 primary	 rat	
hepatocytes	
Grewal	 and	 coworkers	 demonstrated	 that	 LD	 formation	 in	 AnxA6-depleted	 HuH7	
hepatocytes	 displayed	 reduced	 sensitivity	 towards	 the	 pharmaceutical	 inhibition	 of	
cPLA2α,	 using	 the	 cPLA2α-specific	 inhibitor	 MAFP	 (118).	 These	 findings	 suggested	 the	
involvement	of	cPLA2α-dependent	pathways	in	AnxA6-depleted	cells	for	TG	accumulation.	
However,	results	described	above	(Fig.	18)	provided	cPLA2α	phosphorylation	patterns	 in	
HuH7-A6	 and	 HuH7-A6KD	 cells	 that	 did	 not	 correlate	 with	 increased/decreased	 LD	
formation	upon	AnxA6	up-	or	downreguation.	To	initiate	studies	in	other	cell	models	and	
explore	primary	hepatocytes	as	a	potential	model	to	link	cPLA2α	phosphorylation	with	LD	
formation,	 we	 next	 examined	 cPLA2α	 phosphorylation	 in	 OA-loaded	 primary	 rat	
hepatocytes	in	the	presence	or	absence	of	the	cPLA2α-specific	inhibitor	MAFP	(Fig.	19).		
	
Figure	 19:	 Pharmacological	 cPLA2α	 inhibition	 reduces	 cPLA2α	 phosphorylation	 in	 OA-
loaded	primary	rat	hepatocytes.	Primary	rat	hepatocytes	were	treated	±	0.6	mM	OA	for	
24	 h	 and	 additional	 6	 h	MAFP	 as	 indicated.	 Cells	 were	 lysed	 and	 analysed	 by	 western	
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blotting	 for	 phosphorylated	 and	 total	 cPLA2α,	 AnxA6	 and	 b-actin.	 The	 relative	 cPLA2α	
activity	 (P-cPLA2α/total	 cPLA2α),	 and	 AnxA6	 expression	 normalized	 to	 b-actin	 was	
calculated	using	Image	J.	Mean	±	SEM,	n=2.	
	
Therefore,	 hepatocytes	 from	 male	 Sprague-Dawley	 rats	 were	 isolated	 by	 collagenase	
perfusion	 and	 cultured	on	10	 cm2	dishes	 coated	with	 rat	 tail	 collagen	 (149).	 24	h	 after	
plating,	 cells	were	 incubated	with	0.6	mM	OA	overnight	 in	 the	presence	or	 absence	of	
MAFP,	lysed	and	analyzed	by	western	blotting	(Fig.	19)	for	phosphorylated,	total	cPLA2α	
as	well	AnxA6	and	b-actin	expression	levels.	In	contrast	to	the	findings	obtained	from	OA-
loaded	HuH7	hepatocytes	(Fig.	11),	AnxA6	levels	were	slightly	reduced	in	rat	hepatocytes	
in	the	presence	of	OA.	In	addition,	unlike	the	results	obtained	from	HuH7-WT	hepatocytes	
(Fig.	 17),	 cPLA2α	 phosphorylation	 was	 not	 increased	 upon	 OA	 loading,	 but	 cPLA2α	
phosphorylation	displayed	sensitivity	 towards	 the	of	cPLA2α	 inhibitor	MAFP.	Due	 to	 the	
time	 constraints	 of	 this	 project,	 we	 were	 unable	 to	 correlate	 these	 findings	 with	 LD	
formation	 and	 TG	 accumulation.	 These	 findings	 highlight	 once	 more	 the	 differential	
expression	pattern	and	behavior	of	 the	various	hepatocyte	models.	Future	experiments	
will	have	to	identify	the	best	suitable	cell	models	to	identify	how	AnxA6,	possibly	through	
of	cPLA2α-dependent	pathways,	modulates	LD	formation	in	hepatocytes.	
	
 
 
51 
4.	Discussion	
4.1	The	association	of	AnxA6	with	LD	
Subcellular	fractionation	of	rat	liver	tissue	identified	AnxA6	in	LD	fractions	(Chapter	3.2).	
These	 findings	 are	 in	 line	with	proteomic	 profiling	of	 LD	preparations	 isolated	 from	 rat	
liver	 hepatocytes	 as	 well	 as	 mouse	 adipocytes	 (140,	 141).	 Contamination	 with	 other	
organelles,	 in	 particular	 the	 ER,	 often	 undermines	 the	 identification	 of	 LD-associated	
proteins	 from	 subcellular	 fractionation	 procedures,	 but	 immunohistochemistry	 further	
supports	 AnxA6	 to	 be	 localized	 on	 LD	 membranes.	 First,	 AnxA6	 co-localized	 with	 LD	
markers	 in	3T3-L1	adipocytes	 (117),	 and	 second	co-localized	AnxA6	with	 the	LD	marker	
PLIN2	 in	 OA-loaded	 HuH7	 hepatocytes	 (118).	 Interestingly,	 ectopically	 expressed	 and	
fluorescently-tagged	AnxA6	also	co-localized	with	a	fluorescent	ER-marker	protein	that	is	
also	 found	 on	 LD	 (118).	 In	 these	 experiments,	 substantial	 amounts	 of	 AnxA6	were	 not	
only	 located	 on	 LD,	 but	 also	 on	 the	 ER	 of	OA-loaded	HuH7	 hepatocytes.	 Although	 one	
cannot	completely	rule	out	an	‘overspill’	of	overexpressed	AnxA6	in	other	compartments	
in	 these	 experiments,	 this	 could	 indicate	 a	 new	 cellular	 localization	 for	 AnxA6,	 that	
despite	 decades	 of	 intensive	 localization	 studies	 in	 the	 annexin	 field,	 has	 not	 yet	 been	
identified.	 Similarly,	 recent	 studies	 from	Moss	 and	 coworkers	 (130)	 identified	a	pool	of	
AnxA6	proteins	in	mitochondria,	a	novel	 location	that	had	not	been	noticed	earlier.	Yet,	
all	previous	localization	studies	in	cells	or	tissues	from	hepatic	origin	have	not	revealed	an	
association	of	AnxA6	with	LD	(64,	112-114).	This	indicates	that	the	complex	morphology	
of	the	polarized	hepatocyte,	which	 is	generally	 lost	when	culturing	primary	hepatocytes	
or	hepatic	cell	 lines,	 together	with	 the	presence	of	other	cell	 types	such	as	stellate	and	
kupffer	 cells	 in	 tissue,	 probably	 complicate	 the	 identification	of	 smaller	AnxA6	pools	 in	
compartments	 other	 than	 the	 plasma	 membrane	 and	 endosomes.	 In	 addition,	
immunohistochemistry	of	cells	and	tissues	by	electron	or	fluorescence	microscopy	heavily	
relies	on	the	selectivity	of	antibodies,	which	might	not	have	been	suitable	to	detect	a	pool	
of	 AnxA6	 proteins	 in	 the	 ER	 that	 is	 possibly	 post-translationally	 modified	 or	 epitope-
masked	and	not	recognizable	for	currently	available	AnxA6	antibodies.	
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4.2	Membrane	binding	properties	of	AnxA6	that	may	enable	LD	binding		
It	 is	 generally	believed	 that	AnxA6,	akin	 to	all	 other	annexins,	binds	negatively	 charged	
phospholipids	in	a	Ca2+-dependent	manner.	Although	LD	contain	plenty	of	phospholipids	
in	the	limiting	membrane,	this	does	not	seem	to	translate	to	the	binding	of	all	annexins	to	
LD.	 In	 fact,	knowledge	on	 the	possible	association	of	annexins	with	 lipid	droplets	 is	 still	
limited.	 In	 rat	 liver,	 proteomics	 identified	 AnxA6,	 but	 also	 AnxA2,	 in	 LD	 fractions	 (128,	
139).	 Increased	 expression	 of	 AnxA1	 was	 associated	 with	 loss	 of	 LD	 in	 corticol	 cells,	
although	 this	 was	 not	 linked	 to	 the	 physical	 association	 of	 AnxA1	 with	 LD	 (155).	 In	
contrast,	female	AnxA1	KO-mice	displayed	increased	adiposity	after	high-fat	diet	feeding,	
indicating	a	role	for	AnxA1	in	lipid	accumulation	in	adipocytes	(115).	Recently,	the	specific	
association	of	AnxA3	to	LD	 in	hepatocytes	after	hepatitis	C	 infection	was	observed.	This	
does	not	seem	to	affect	LD	formation,	but	appears	critical	for	virion	assembly	(156).	The	
dynamic	 and	 reversible	membrane	 association	 of	 AnxA6	 could	 translate	 transient	 Ca2+-
signals	into	membrane	re-organizations	or	signal	complex	assembly/disassembly.	In	3T3-
L1	 adipocytes,	 the	 LD	 association	 of	 AnxA6	 is	 coupled	 to	 epinephrine-inducible	
phosphorylation	of	hormone	sensitive	lipase.	This	pathway	is	a	driver	of	lipolysis	and	FA	
mobilization	from	LD	in	a	Ca2+-sensitive	manner	(117).	While	this	observation	would	be	in	
line	 with	 the	membrane	 binding	 ‘dogma’	 of	 annexins,	 in	 non-adipose	 tissue,	 including	
hepatocytes,	hormone	sensitive	 lipase	does	not	play	a	significant	role	 in	FA	metabolism	
(157).	Moreover,	in	the	immunofluorescence	studies	performed	by	Grewal	and	colleagues	
(118),	 AnxA6	 localization	 on	 LD	 membranes	 was	 not	 inhibited	 by	 Ca2+	 depletion,	
suggesting	 Ca2+-independent	 membrane	 binding	 properties	 of	 AnxA6	 to	 enable	 LDs	
association.	Phosphatidylserine,	then	phosphatidylinositol	and	phosphatidic	acid,	and	to	a	
minor	extend	phosphatidylethanolamine	and	arachidonic	acid	bind	to	AnxA6	(64,	67,	74,	
98,	158).	However,	acidic	pH	and	cholesterol,	as	shown	by	Grewal	and	colleagues	as	well	
as	 others,	 also	 promote	AnxA6	membrane	 association	 (74,	 81,	 83).	 Yet,	 the	 LD	 surface	
layer	 predominantly	 contains	 phosphatidylcholine	 (50–60%),	 phosphatidylethanolamine	
(20–30%),	both	not	preferred	by	AnxA6,	and	only	minor	amounts	of	phosphatidylinositol	
(<2%)	(44,	159).		
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Hence,	 how	 AnxA6	 can	 bind	 to	 LD	 is	 still	 unclear,	 but	 LD	membranes	 from	 HuH7	 and	
HepG2	hepatocytes	have	been	shown	to	contain	significant	amounts	of	 free	cholesterol	
(159,	160).	As	outlined	in	the	Introduction	(Chapter	1.5.1),	Ca2+	is	not	required	for	AnxA6	
to	 bind	 cholesterol-rich	membranes	 (64,	 81,	 83),	 and	 this	 feature	may	 allow	 AnxA6	 to	
associate	with	 LDs	during	FA	 loading.	Another	possibility	 could	be	 that	AnxA6	does	not	
bind	 to	 LD	 lipids,	 but	 enters	 into	 complexes	with	 LD-associated	 proteins	 (64,	 112-114),	
such	 as	 vesicular	 transport	 proteins	 (small	 GTPases,	 SNAREs),	 motor	 proteins,	 protein	
kinases	(mitogen-activated	protein	kinase,	protein	kinase	C).	Some	of	those	LD-associated	
proteins	have	been	documented	as	AnxA6	 interaction	partners	 (64,	67,	98,	158).	Other	
candidates	could	be	lipid-modifying	enzymes,	including	cPLA2α	(see	below).	
	
Despite	 the	 aberrant	 upregulation	 of	 AnxA6	 in	 the	 HuH7	 hepatocytes,	 this	 cell	 line	 is	
commonly	used	 to	examine	hepatic	 LD	biology	 (161-163).	Alike	other	hepatic	 cell	 lines,	
transformation	 of	 hepatocytes	 is	 associated	 with	 the	 loss	 of	 hepatocyte	 features,	 in	
particular	cell	polarity.	Hence,	alike	HepG2	and	other	hepatic	cell	lines,HuH7	cells	do	not	
display	 the	 characteristic	 morphology	 of	 polarized	 primary	 hepatocytes.	 Nevertheless,	
this	cell	line	is	well	believed	to	reflect	a	good	model	for	hepatic	lipid	metabolism.	Indeed,	
similar	 to	 the	 reduced	 LD	 numbers	 observed	 in	 AnxA6-KD	 HuH7	 hepatocytes,	 we	 also	
observed	less	FA	accumulation	in	primary	hepatocytes	isolated	from	the	AnxA6-KO	mice	
(117).	Moreover,	AnxA6	deficiency	 in	mice	was	associated	with	significantly	 reduced	LD	
numbers	in	AnxA6-/-	liver	sections	(117).	Taken	together,	data	from	AnxA6	knockdown	in	
HuH7	 hepatocytes,	 AnxA6-deficient	 primary	 hepatocytes	 and	 AnxA6-KO	 liver	 sections	
suggest	that	loss	of	hepatic	AnxA6	is	associated	with	a	reduced	ability	to	generate	LD.	
	
	
4.3	 AnxA6	 upregulation	 increases	 triglyceride	 accumulation	 in	 HuH7	
hepatocytes	
The	 analysis	 of	 isolated	 LD	 fractions	 from	 OA-loaded	 HuH7	 hepatocytes	 revealed	 that	
AnxA6	 overexpression	 increased	 triglyceride	 accumulation	 (Chapter	 3.1).	 These	
biochemical	determinations	of	neutral	lipid	in	a	purified	fraction	enriched	with	LD	support	
the	 other	 studies	 from	 the	 Grewal	 group	 based	 on	 fluorescence	 microscopy	 and	 flow	
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cytometry	that	identified	AnxA6	upregulation	in	HuH7	hepatocytes	to	correlate	with	high	
LD	 numbers	 upon	 incubation	with	OA	 (118).	 Vice	 versa,	OA	 loading	 of	 AnxA6-depleted	
HuH7	 cells,	 as	 well	 as	 analysis	 of	 primary	 hepatocytes	 from	 the	 AnxA6-KO	 mice,	 was	
associated	with	less	LD	formation.	In	these	studies,	the	fatty	acid	receptor	CD36,	as	well	
as	ATGL	and	fatty	acid	synthase	(FAS)	were	expressed	at	comparable	levels	in	HuH7-WT,	
HuH7-A6,	 and	 HuH7-A6KD	 cells	 (118).	 Hence,	 aberrant	 cellular	 uptake	 of	 FA,	 or	 FA	
mobilization	 from	LDs	or	de	novo	 synthesis	are	unlikely	 to	explain	altered	LD	 formation	
upon	AnxA6	up-	or	downregulation.		
	
Given	 that	 stable	 AnxA6	 overexpression	 or	 knockdown	were	 used	 as	 gain-	 and	 loss-of-
function	 models	 to	 address	 a	 potential	 role	 of	 AnxA6	 in	 triglyceride	 metabolism,	 one	
would	have	to	consider	if	these	cell	models	could	represent	physiological	settings.	At	least	
in	HuH7-WT	hepatocytes,	we	observed	a	trend	of	AnxA6	upregulation	in	the	presence	of	
OA	 (Chapter	 3.3),	 indicating	 that	 increased	 availability	 of	 FA	 might	 trigger	 AnxA6	
upregulation	 to	 allow	 increased	 LD	 formation	 for	 neutral	 lipid	 storage.	 However,	 OA	
loading	 of	 AML12	 mouse	 hepatocytes	 and	 primary	 rat	 hepatocytes	 did	 not	 reveal	
elevated	 AnxA6	 protein	 levels	 upon	 OA	 loading	 (Chapter	 3.4).	 Likewise,	 AnxA6	 mRNA	
expression	was	 comparable	 in	HuH7-WT	 and	HepG2	 in	 the	 presence	 or	 absence	 of	OA	
(Chapter	 3.5).	 This	 may	 indicate	 that	 AnxA6	 protein	 upregulation	 in	 OA-loaded	
hepatocytes	may	 be	 restricted	 to	 the	 HuH7	 cell	 line,	 with	 limited	 relevance	 for	 AnxA6	
function	in	vivo.		
	
Indeed,	 the	 low	 endogenous	 AnxA6	 levels	 in	 HuH7-WT	 hepatocytes	 (Chapter	 3.2,	 3.6)	
may	not	reflect	the	high	AnxA6	levels	 in	 liver,	which	are	generally	believed	to	represent	
constitutive	gene	expression	with	little	response	to	metabolic	and	physiological	changes	
(114,	116,	151,	164).	 In	 support	of	 the	 latter,	AnxA6	protein	 levels	 in	mouse	models	of	
obesity,	 insulin	 resistance,	 diabetes	 and	 fatty	 liver	 were	 not	 significantly	 different	 to	
controls.	 	 Grewal	 and	 coworkers	 also	 found	hepatic	 AnxA6	 levels	 unaffected	 in	murine	
nonalcoholic	steatohepatitis	and	human	liver	fibrosis	(151).	Despite	the	lack	of	changes	in	
AnxA6	 expression	 in	 all	 these	 studies,	 one	 could	 envisage	 that	 metabolic	 stress	 could	
impact	on	the	membrane	binding	properties	of	specific	pools	of	AnxA6	proteins.	Thereby	
high	AnxA6	 expressing	 cells	 could	 respond	 to	 changes	 to	 the	 environment	 through	 the	
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remodeling	of	the	cellular	distribution	and	repertoire	of	AnxA6	interactions.		
	
In	addition	to	changes	in	the	localization	and	function	of	existing	pools	of	AnxA6	proteins,	
several	 findings	 also	 suggest	 that	 certain	 metabolic	 stress	 conditions	 may	 alter	 AnxA6	
protein	levels.	For	instance,	in	livers	from	obese	and	female	type	2	diabetics,	but	also	in	
Niemann-Pick	Type	C	(NPC)	-deficient	mice	or	after	high-fat	ketogenic	diet	feeding,	AnxA6	
levels	 were	 upregulated	 (165-168).	 In	 contrast,	 yet	 also	 linked	 to	 NAFLD,	 AnxA6	
expression	 was	 substantially	 reduced	 in	 hepatocellular	 carcinoma	 (151),	 hepatic	 cells	
incubated	 with	 fibrates	 (169),	 or	 leptin-treated	 ob/ob	 mice	 (170).	 These	 examples	
highlight	 that	 some	environmental	 stress	or	disease	conditions	may	 indeed	alter	AnxA6	
expression.	Based	on	our	findings,	this	could	affect	liver	capacity	to	store	neutral	lipids.		
	
4.4	The	potential	role	of	cPLA2α	in	AnxA6-dependent	LD	formation	
The	results	presented	here,	together	with	the	data	from	Grewal	and	colleagues	provided	
in	 the	Cairns	et	 al.	 (2017)	 study,	 strongly	 support	 that	high/low	AnxA6	 levels	modulate	
the	 capacity	 of	 hepatocytes	 to	 store	 neutral	 lipids.	 Yet	 the	 underlying	mechanism	 still	
remains	 unclear.	 Based	 on	 expression	 studies	 described	 above,	 AnxA6	 to	 affect	 FA	
uptake,	 mobilization	 or	 de	 novo	 synthesis	 appears	 unlikely	 (118).	 Given	 that	 AnxA6	
modulates	 the	 organization	 of	 membrane	 domains	 in	 other	 compartments	 [38,	 51],	
AnxA6	binding	to	LD	may	alter	the	organization	of	lipids	in	the	LD	membrane,	modifying	
the	activity	of	lipid-modifying	enzymes	that	allow	entry	and	exit	of	FA	into	LD.	This	could	
also	include	early	steps	in	LD	formation,	when	cPLA2α-dependent	pathways	are	needed	to	
promote	budding	of	LD	vesicles	from	the	ER.	In	support	of	this,	pharmaceutical	inhibition	
of	cPLA2α	in	AnxA6-depleted	HuH7	hepatocytes	did	not	affect	FA	accumulation	(118).		
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Figure	20:	Potential	models	 for	AnxA6	to	regulate	LD	formation	via	cPLA2α-dependent	
pathways.	 AnxA6	 could	 affect	 cPLA2α-dependent	 LD	 formation	 via	 (1)	 direct	 protein-
protein	 interaction	 in	 the	 ER,	 or	 indirectly	 through	 the	 regulation	 of	 (2)	 cPLA2α	
phosphorylation	 and	 activity,	 or	 (3)	 the	 cholesterol-dependent	 cellular	 distribution	 and	
consequently,	 the	 availability	 of	 cPLA2α	 to	 promote	 LD	 formation.	 See	 text	 for	 details.	
Figure	modified	from	(39).		
	
As	depicted	 in	the	model	above,	we	envisage	at	 least	three	scenarios	how	AnxA6	might	
act	 through	 cPLA2α	 in	 order	 to	 modulate	 LD	 formation.	 First,	 given	 the	 proposed	 LD-
forming	 activity	 of	 cPLA2α	 in	 the	 ER	 (39,	 42,	 43),	 and	 our	 recent	 finding	 of	 AnxA6	
colocalization	with	ER	markers	 (118),	 interaction	of	AnxA6	with	 cPLA2α	 in	 the	ER	might	
exist.	 Indeed,	 other	 annexins	 like	AnxA1	 and	AnxA2	 can	 inhibit	 PLA2	 proteins,	 including	
cPLA2α,	 most	 likely	 through	 protein-protein	 interaction,	 or	 competition	 for	 membrane	
phospholipids,	Ca2+	or	other	shared	substrates	 (64,	84,	171).	However,	based	on	earlier	
studies	from	the	Grewal	group,	direct	 interaction	of	AnxA6	and	cPLA2α	appears	unlikely	
(84).	Second,	as	AnxA6	regulates	Erk1/2	signaling	(61,	64,	67),	and	Ser505	phoshorylation	
of	cPLA2α	is	mediated	by	Erk1/2	to	increase	arachidonic	acid	release	(39,	40,	42,	43),	we	
then	speculated	that	AnxA6	may	regulate	cPLA2α	via	Erk1/2.	However,	despite	OA	loading	
increasing	Ser505	cPLA2α	phosphorylation,	we	observed	a	trend	of	AnxA6	upregulation	to	
reduce	 cPLA2α	 phosphorylation,	 while	 AnxA6	 depletion	 generally	 showed	 elevated	
phosphorylated	Ser505	cPLA2α	levels	(Chapter	3.8-3.9).	These	trends	argue	against	AnxA6	
regulating	 cPLA2α	 acitivity	 via	 Erk1/2	 signaling	 in	 the	 context	 of	 LD	 formation.	 Indeed,	
cPLA2α-induced	positive	membrane	curvature	rather	than	arachidonic	acid	release	drives	
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budding	 for	 LD	 formation	 (39,	42,	43).	Moreover,	 ceramide	kinase	 -dependent	 c-Jun	N-
terminal	 kinase,	 and	 not	 Erk1/2,	 seems	 to	 phosphorylate	 and	 stimulate	 cPLA2α	 for	 LD	
formation	(39,	42,	43).	 	Third,	AnxA6	overexpression	causes	cholesterol	accumulation	 in	
late	 endosomes,	which	 indirectly	 re-distributes	 cPLA2α	 proteins	 inside	 cells	 (64,	 67,	 84,	
127),	providing	more	cPLA2α	in	the	cytosol.	The	changes	in	cholesterol	distribution	and	its	
consequences	 on	 cPLA2α	 localixzation	 could	 readily	 affect	 its	 availability	 for	 the	 ER	 for	
membrane	remodelling	required	for	LD	budding	events.	
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5.	Conclusions	
	
The	 presence	 of	 AnxA6	 in	 lipid	 droplet	 fractions	 (Aim	 1),	 together	 with	 the	 trends	 of	
increased	 TAG	 accumulation	 upon	 AnxA6	 overexpression	 (Aim	 2)	 provide	 additional	
support	for	AnxA6	to	modify	the	ability	of	hepatocytes	to	store	neutral	lipids.	Vice	versa,	
AnxA6	depletion	in	primary	hepatocytes	and	liver	is	associated	with	reduced	LD	numbers	
(118).	However,	 expression	 studies	 in	 cell	 and	 animal	models	 do	not	 indicate	 that	 lipid	
anomalies	 commonly	observed	 in	obesity,	 diabetes	or	metabolic	 syndrome	may	 impact	
significantly	 on	 AnxA6	 expression	 levels	 (Aim	 3-4),	 nor	 do	 the	 underlying	 mechanisms	
seem	to	be	associated	with	alterations	in	cPLA2	activity	(Aim	5).	
	
Future	 studies	will	 need	 to	 validate	 findings	 presented	 here,	 closely	 examining	 hepatic	
AnxA6	 mRNA	 and	 protein	 expression	 under	 normal	 and	 disease-like	 conditions.	 As	
outlined	 in	 our	 recent	 study	 (118),	 AnxA6	 expression	 was	 unchanged	 in	 murine	
nonalcoholic	 steatohepatitis	 and	 human	 liver	 fibrosis	 (62),	 but	 lower	 in	 hepatocellular	
carcinoma,	with	links	to	NAFLD	(62).	Also,	from	the	NCBI	Gene	Expression	Omnibus	data	
AnxA6	levels	were	found	to	elevated	in	liver	biopsies	from	obese	and	in	women	with	type	
2	diabetes	(64,	65),	mice	lacking	Niemann-Pick	Type	C	(NPC)	or	after	feeding	with	a	high-
fat	 ketogenic	 diet	 (67,	 70).	 In	 contrast,	 peroxisome	 proliferator-activated	 receptor	
agonists	 (74),	 or	 leptin-treated	 ob/ob	mice	 (77)	display	 AnxA6	 downregulation.	 Hence,	
certain	stresses	or	diseases	conditions	may	differentially	affect	AnxA6	expression	 levels.	
These	 findings	could	be	extended	 to	 the	underlying	causes	at	 the	 transcriptional	 levels,	
such	as	analysis	of	miRNA	expression	patterns	or	epigenetic	 changes.	 These	 changes	 in	
hepatic	AnxA6	levels	could	impact	on	the	ability	of	hepatocytes	to	store	neutral	lipids.	
	
Future	 studies	 should	 also	 dissect,	 if	 AnxA6	 affects	 LD	 formation	 via	 direct	 interaction	
with	 cPLA2α	 or	 other	 ER-resident	 proteins.	 Alternatively,	 indirect	 pathways	 targeting	
phosphorylation	 or	 cholesterol-sensitive	 localization	 of	 cPLA2α	 also	 have	 to	 be	
considered.	In	particular	the	latter	possibility	is	supported	by	several	studies	that	connect	
late	endosomal	cholesterol	with	LD	formation,	hepatic	FA	and	TAG	metabolism	(160,	172,	
173).	
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Figure	21:	Possible	opposite	functions	of	AnxA6	in	adipose	and	liver	tissue.	In	adipocytes,	
AnxA6	elevation	 impairs	 triglyceride	 (TG)	storage,	while	AnxA6	knockdown	promotes	TG	
storage	 and	 reduces	 basal	 lipolysis.	 In	 hepatocytes,	 AnxA6	 elevation	 promotes	 TG	
accumulation,	while	AnxA6	knockdown	reduces	TG	accumulation.	
	
In	summary,	down	regulation	or	inhibition	of	hepatic	AnxA6	could	provide	opportunities	
to	lower	the	risk	of	developing	NAFLD.	Interestingly,	using	glucocorticoid	steroids	such	as	
prednisone,	recent	reports	 identified	the	opportunity	of	up	regulating	AnxA6	expression	
levels	 for	 the	 treatment	 of	 chronic	 muscle	 conditions	 such	 as	 Duchenne	 muscular	
dystrophy	 (174).	These	exciting	 findings	 indicate	that	manipulation	of	AnxA6	expression	
levels	 for	 therapeutic	 purposes	 may	 be	 feasible	 in	 clinical	 settings.	 However,	 these	
therapeutic	 interventions	most	 like	need	 to	occur	 in	a	 tissue-specific	manner,	as	AnxA6	
multifunctionality,	 often	 exemplified	 by	 variations	 in	 AnxA6	 expression	 levels	 within	 a	
complex	 organism	must	 to	 be	 coordinated.	 Indeed,	 the	 diversity	 of	 AnxA6	 functions	 is	
illustrated	 in	adipocytes,	where	AnxA6	upregulation	 impaired	 triglyceride	storage,	while	
AnxA6	 knockdown	 promoted	 triglyceride	 storage	 and	 reduced	 lipolysis	 (117).	 These	
observations,	possibly	due	to	different	interaction	partners	in	adipose	versus	liver	tissue,	
might	reflect	opposing	activities	of	AnxA6	in	the	central	organs	for	triglyeride	metabolism	
(Fig.	 21).	 Thus,	 developing	 therapeutic	 strategies	 via	 mechanism	 that	 target	 AnxA6	 in	
complex	 physiological	 settings	 will	 need	 further	 investigation	 to	 improve	 basic	
understanding	how	AnxA6	impacts	on	whole	body	lipid	homeostasis.	Nevertheless,	with	
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the	development	of	gene	targeting	approaches	that	specifically	eliminate	the	expression	
of	 genes	 exclusively	 in	 the	 liver	 or	 other	 organs,	 one	 can	 envisage	 that	 tissue-specific	
inhibition	of	AnxA6-dependent	pathways	may	be	feasible	in	the	future.	
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7.	Appendix	
